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ABSTRACT
This overview has provided an account of evolutional changes of an experience-based traditional medical practice of traditional Chinese
medicine (TCM) towards modernisation to keep up with recent advances in analytical and biomedical sciences, and information technology,
which may help readers to understand why applying biomedical research methodology to TCM modernisation, while maintaining the
experience-based concepts, principles and heritage of TCM’s personalised health and medical approaches in balancing body’s functions with
physical and mental harmony when facing environmental changes, can contribute to gain global appreciation and acceptance of TCM in
healthcare. It is envisaged that such future development and integration with biomedicine-based main-stream medicine (MSM) in practice will
provide valuable medical care in the development of future personalised health and medicine as well as TCM product development.
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INTRODUCTION
This paper describes the author’s research paths from
pharmaceutical to integrative approaches in basic and clinical
research of main-stream medicine (MSM) initially, then
Traditional Chinese Medicine (TCM). Through these long
and winding paths of working in academic institutes,
government bodies and hospitals, in both the northern and
southern hemispheres over the past years, the author has
collectively summarised his experience of the evolution to the
present-day medicine through literature publications and
own research outcomes. With this knowledge and experience
collated over the decades, some recommendations are
provided in this overview the best way forward to steer the
global role of TCM in healthcare in the 21st century.
The initial part of the overview deals with short accounts
on the development of both MSM and TCM in order to
understand their contributions in treating human diseases
from evolution of ethnic culture and philosophy. The
different views of TCM in the West during the mid-1990s
that stimulated a debate on ‘For and Against’ of its role in
health amongst the public, academia and legal bodies is a
mile-stone for a closer look of TCM in terms of quality,
safety and efficacy at large since that period.
The recent advances of technology in biomedical sciences are
consequential to the human genome project, and analytical/
instrumental sciences that allow imminent measurement of
events occurring in cell/organ programming, and computa‐
tional sciences that provide databases of both biomedical and
analytical parameters for further elucidation and determination
of research outcomes, have collectively and indirectly brought
the two vastly dissimilar medical concepts to another debate of
‘For and Against’ in personalised integrative healthcare.
A large number of currently used pharmaceutical medicines
are obtained from medicinal plants or natural sources[1]. The
development of current practice and pharmaceutical medicines
in MSM has a comparatively short history: medieval medicine
initiated in Europe into a science-based discipline dates back
less than 200 years[2]. This rapid rate of success depended
mainly on the advancement of physical sciences and techno‐
logy[3]. Many pharmaceutical medicines were introduced
initially via activity-screening from extracts of medicinal plants
and phytochemical isolation and subsequently followed by
chemical synthesis of the isolated active compounds. With the
help of chemical synthesis and fitting novel chemical entities
into quantitative structure-action analysis (QSAR)-models or
protein-enzyme models a series of chemical analogues can be
screened for new drug development. The successful discovery
and development of penicillin (1928–1945)[4], which has been
coined as amilestone in 20th century pharmaceutical chemistry,
has stimulated introduction of many pharmaceutical drugs
during the 1960s, therapeutic armament to develop and
improve MSM in the developed countries worldwide, while
the developing and under-developed countries/regions have
relied on their own ethnic/traditional medicines mainly from
medicinal plants even nowadays[5].
In recent years the pharmaceutical industry has produced
fewer new agents for treatment of chronic diseases related to
metabolic syndromes (cardiovascular complications, diabetes,
obesity), rheumatoid arthritis, aging-related degenerative dis-
orders such as Alzheimer diseases, dementia, Parkinson’s
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diseases and other high burdendiseases such as various cancers,
infectious diseases caused by drug-resistant microbial infec-
tions and others through sexual contacts or contaminated
blood such as hepatitis and related carcinomas and HIV.
Among many factors the root causes of few new drugs are:
relentless health economics pressure; increasing regulatory
hurdles; immature state of knowledge and molecular reduc-
tionism and management reductionism & diseconomies of
scales[6]. Such approach to identify small molecules for drug
development becomesmore andmore expensive. Most nation-
al health systems worldwide have suffered from the burden of
high cost of pharmaceuticalmedicines in both primary care and
secondary care since the 1990s. Table 1 briefly summarises the
key events of evolution and progress of pharmaceutical
medicines in OM from ancient time to the future.
The Keeping of the 5000 Years Old TCM
in Line with Advances in Science and
Technology
TCM as one of the oldest medical traditions since 2800 BC has
been practised to maintain health and treat diseases in the
Chinese communities and recently adopted by others world-
wide. Table 2 concisely summarises the historical development
of TCM since ancient times. Nowadays, Chinese materia
medica (CMM) and proprietary products of TCM composite
formulae (PCM), acupuncture and related medical manipula-
tion (Tuina and related physical therapies), together with life
styles (consuming CMM functional foods, practising Taichi, or
Qigong meditation) are often used in TCM practice, co-
existing with MSM in China and some regions in the Far East.
Though used by the public on their own accord, TCM has not
been recognised officially in some regions such the European
Union and North America as part of the healthcare system
run by main stream MSM practice. Such circumstance has
delayed the development of traditional medicine in these
regions in comparison with that in Australia, Japan (as kampo
medicine), Korea (as oriental medicine) and some European
countries. The non-recognition can be considered as obstacles
for delay in the development and modernisation of TCM in
general worldwide[7].
Meanwhile, two unrelated phenomena in medical pro-
gresses were observed: Firstly, the population in the well-
developed countries have turned to complementary and
alternative medicines (CAM) and TCM has been one of the
key CAM disciplines attracting most attention as evidenced by
a recent overview on a 2010-2015-2025 survey and predic-
tion[8]. Secondly, the human genome programme completed
in 2003 has introduced significant advancement of biomedical
and analytical technology to further the understanding of the
nature of ill-health and offered new hopes to the big
pharmaceutical organisations to develop new medicines based
on functional genomics, proteomics and systems biology/
medicine for treatments of diseases[9]. Indirectly such advances
of biomedical and analytical technology may have also
influenced the development of TCM and offered opportunity
for modernisation to keep up with such advances, which help
to convert an experience-based practice towards evidence-
based medical practice in order to play a role to integrate into
main stream medicine while maintaining its traditional holistic
principles for maintaining good health[10].
This overview addresses these key issues and attempts to
propose ways for future research and development for TCM
into the 21st century. The impact will certainly be moderni-
sation in every aspect of the disciplines to cope with the fast
growing demand in quality medicines while maintaining the
traditional principles of TCM health holism. Several major
areas, which are essential for global development of TCM, are
listed for discussion.
Challenges Towards Diverging Opinion
on TCM in the 1990s
1. Lack of understanding of TCM principles
in health and disease
The holistic approaches of TCM in diagnosis and treatment
of diseases and maintaining good health is in contrast to that
of MSM. Practice of MSM is based on modern anatomy,
molecular cell biology and is characterised by a reductionist
approach in analysis and diagnosis of health and diseases. As
TCM was established long before the advent of modern
science, involving validation and experiences gained over
thousands of years, it represents an area of medicine that is
more experienced-based with the environmental and philo-
sophical approaches than based on conventionally scientific
aspects. Although TCM has played an indispensable role in
maintaining the health of people in China and several Asian
regions, its value remains largely unproven according to
biomedical sciences and many existing systematic reviews or
meta-analyses are often inconclusive due to the less stringent
clinical design not related to MSM criteria for randomised
clinical trials (RCT). This deficiency has led to criticism
domestically and internationally. Reasons for underdeveloped
TCM research during this period are manifold, including
subjective and personalised TCM diagnosis, which is often
incompatible with the conventional RCT methodology for
clinical research; the complexity and wide diversity of herbal
medicines and diseases; as well as the difficulty of choosing
correct controls for complex herbal remedies prepared from
CMM and acupuncture, etc. Furthermore, lack of research
funding and a worldwide shortage of qualified researchers
outside the Chinese mainland who understand both TCM
and modern biomedical technologies should never be under-
estimated. These situations have been improved recently as
more scientists and practitioners have taken interest to find
out how TCM works in their quests for evidence endeavours.
2. Observations on the increasing appreciation
and scepticism of TCM
In the west increasing uses of Chinese medicines have created
both acceptance and scepticism of TCM practice that have
initiated a major debate in medical cycles since the successful
randomized clinical trial on the use of ten prescription CMMs
on atopic eczema was published in 1992[11]. Quite separately
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Table 1. The Evolution of Main Stream Medicines in Europe and Other Developed Countries (Modified from ref.[2]).
ORIGIN: Ancient traditional medical practices of various ethic groups
3000 BC • Influence of Babylonian and Egyptian cultural and medical records provided initial contributions.
500 BC • In Europe and surrounding regions, the Greek inheritance of Babylonian and Egyptian medicine,
with influence from the East (Ayurvedic and Chinese medicine) led progress.
510 BC to 476 AD • The Roman Empire brought prosperity, law, the Latin language and Christianity to Europe and the
Mediterranean region, but adapted medical practice from the Greek physicians.
476 AD to 14th Century • Arabic influence on translation and compilation of Greek medical works into Arabic, forming a
source of knowledge for Main Stream medicine from the Dark Age, and surviving through the
Middle Age (4 to 8th century) to modern times.
14th to 17th Century • Influence of the Renaissance, started in Italy to France, increasing/accumulating knowledge of
anatomy and physiology of human body.
• Translation of Arabic medical literature to Latin.
• Influence of the evolution of physical sciences, mainly due to Galileo Galilee (1564–1642), Isaac
Newton (1642–1727).
Late 18th Century to
19th Century
• Influence of the Industrial Revolution in Britain (1830), then in France & Belgium (after 1870) and in
Russia (after 1900).
• Modernisation of industry, social and economic issues.
• Development of natural sciences, such as chemistry, mathematics and physics, laid the groundwork
for nowadays medical developments.
• This had a profound influence on the progress of modern medicine from medieval practices (which
was based mostly on mainly religious and superstitious beliefs) into a 20th century science-based
discipline, in only 100 years.
• Isolation and identification of active ingredients from medicinal plants that were used over centuries
and discovery of endogenous compounds with medicinal uses from animal sources. Leading to the
first therapeutic revolution of the 20th century.
GROWTH: Period of Rapid Medical Advances. Some key points are listed
Late 19th to 20th century • Development of public health legislation and education.
• Development of standardized and vaccination for preventative measures.
• Development of anaesthetics and anaesthesia (William Morton, 1846) helping surgical progress.
• Development of microscope helping bacteriology and sterile techniques that helped indirectly the
progress of medical surgery (Robert Koch, Louis Pasteur, and Joseph Lister).
• Discoveries of chemotherapeutic agents stimulated development of rational therapeutics –
emerging pharmaceutical industry.
1905 • Salvarsan’s selective toxicity against syphilis (1905) led the introduction of sulphonamides.
Early 1900s • Prontosil’s control of streptococcal infections led to the launch of most effective less toxic
sulphapyridine in 1938, other antimicrobials included penicillin (1928), streptomycin (1943)
chloramphenicol (1949).
• Development of rational therapeutics continued under the influence of bioassays and receptor
assays using isolated tissues for endogenous neurotransmitters, hormones etc.
• Discovery of autonomic functions (due to discovery of pharmacological actions of acetylcholine by
Henry Dale in 1940) let to introduction of muscle relaxants, cardiovascular drugs.
• Discovery of insulin (action in 1921 by Banting and Best; structure clarified in 1955) standardised by
blood sugar concentrations in mice and isolated rat diaphragm.
• Discovery of neuroleptics for treatment of schizophrenia (chlorpromazine in 1950).
• Discovery of tricyclic antidepressants for treatment of depression (Imipramine 1952).
• Introduction of benzodiazepine as tranquillisers and hypnotics (1960’s), many other modern
synthetic analogues for almost all diagnosed diseases.
1961 • The incidence of thalidomide induced malformation of new-born nearly halted all new drug
development due to teratogenic effects. Better quality assurance was demanded for testing toxicity,
mutagenicity, carcinogenicity and teratogenicity.
1970s • Various government interventions on standards and quality assurances in laboratory testing and
practice had a great influence on all industries. Good laboratory practice (GLP) guidelines were set
to promote and co-ordinate experiments for the purpose of bringing about safety and quality
control.
1970 to 1990’s • Setting up legislation by various governments of developed countries to implement Good
Manufacturing Practice (GMP) and Good Clinical Trial Practice (GCTP); launch of ICH for new
drugs development in 1990.
20th to 21st Century &
The Future
• Further development of biotechnology in gene therapy, diagnosis and biotechnological
pharmaceuticals.
• Development of vaccines against parasites of medical concern.
• Preventive medicine, reducing cost of primary healthcare.
• Improvement of quality of life.
• New medicine for healthcare: Inclusion of quality–assured traditional medicines in
integrative medical practice?
• Towards personalized medicine/precision medicine
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Table 2. The Evolution of Traditional Chinese Medicine (TCM) towards Integrative Healthcare (Modified from ref[2])
PERIOD
Since 2800 BC
The Three Noticeable Legendary and Dynastic Periods
• The Shen Nong Period: development of agriculture and use of medicinal plants by
Shen Nong (A Plowman folklore hero) for treatment of illnesses;
• The use of ‘Bian-Shi’ as sharp stones and moxa for relief of minor complaints/pains
marked the origin of acupuncture and moxibustion.
2697 to 1 BC • Development of techniques for diagnosis and treatment by the first Huang Di
(Emperor) and his cabinet members in about 2697 BC;
• Compilation by many physicians and pharmacists (under the name of Huang Di, in
about 100 BC) of Huang Di Nei Jing (The Inner Canon of the Yellow Emperor) that
consists of 2 main parts (Sù wèn and Líng shū) recording the Yin Yang Theory, Wu Xing
(Five Elements) Theory, and related information, in questions and answers form, on
pathology, signs and symptoms (collectively as syndromes), causes of diseases, whole
body and the environment, and other holistic principles of traditional Chinese medicine.
• Compilation of Shen Nong Ben Cao Jing (The Herb Classic of the Divine Plowman is
the earliest Materia Medica in China) by various scholars in about 1BC listing of 365
herbal materials (252, 67, and 46 plant, animal and mineral sources respectively) and
recording procedures and principles of processing, mixing and formulating them.
221 BC to 1911 AD Non-stop development and evolution of Chinese medicine and pharmacy throughout; can
be summarised by the publication of valuable pharmacopoeia and other medical texts. Each
dynasty headed by some enlightening emperors would update and compile these texts with
the consequence of including more natural products for use as materia medica; only well
known ones (including those translated to other languages) are listed here:
• Shang Han Lun (Treatise of Cold, Diseases and Miscellaneous Disorders written by
Zhang Zhong-Jing during 25 to 220 AD), a classical dispensary handbook describing
syndrome differentiation, treatment, and use of material medica, is the foundation of
composite prescription (Known as Formulary). Together with Huang Di Nei Jing and
Shen Nong Ben Cao Jing, the Shang Han Kun text plays a vital role in the development
of Chinese medicine for later generations.
• Tang Ben Cao (Tang Xin Xiu Ben Cao; Tang Dynasty Materia Medica commissioned
by the Emperor and written by Su Jing with 23 other medical and pharmacy scholars
who rectified the information and knowledge) is considered to be the earliest
pharmacopoeia in the world. It consists of 54 chapters, 850 herbal descriptions with 20
imported herbs (probably via the Silk Road); influencing development of medicine in
Korea and Japan; being 800 and 1100 years earlier than the pharmacopoeia from Italy
(1499AD) and Denmark (1772 AD) in Europe.
• Ben Cao Gang Mu (Compendium of Materia Medica, authored by Li ShihZhen, a
medical and pharmaceutical practitioner, around 1518 to 1593 AD), consists of 52
volumes, 1892 natural products (350 from minerals, 1099 from plants, 443 from
animals), 11096 Fu Fang (composite prescription formulae). This Compendium was
published in 1596 AD and was brought to Europe and Japan, translated initially to
Latin then in English, French, German and Russian.
• Chinese medicine in other countries influenced neighbouring countries such as Korea
and Japan as early as the period in Qin dynasty (221 to 207 BC) and 57 AD respectively
• Acupuncture was introduced into Europe in the 16th century when some orthodox
physicians picked up the techniques in Japan when trading in the Far East was started via
the Dutch East India Company.
POST-DYNASTIC PERIOD
1911 to 1950s
The Influence of Main Stream Medicine and Decline of Traditional Chinese Medicine
• The collapse of Qing Dynasty introduced chaos to the country leading to western
influence/invasion of nearly all aspects of life including political, social and healthcare
matters.
• Formation of the Republic in 1911 and introduction of orthodox medicine practically
eliminated the practice of Chinese medicine.
• Knowledge of acupuncture was made more known to other parts of the world when
trade was started with European countries.
PERIOD OF RE-INTRODUCTION
1950 to 1980s
The Influence of Poor Economic after 2nd World War and the Civil War
• The PRC government re-emphasised the importance of TCM from 1956 onwards due
to economic and technical limitation for pharmaceutical drugs.
• Gradual modernisation and regulation of both western orthodox medicine (OM) and
traditional Chinese medicine (TCM) interfered in between by the cultural revolution
from the 1970s to 1980s in conjunction with the nation-wide economic development.
• Setting up of specialist universities of TCM in major cities in key parts of China: Beijing
(north) Chengdu (west), Nanjing (middle), Shanghai (East) and Guangzhou (south)
while maintaining provincial colleges of TCM throughout the country.
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during this similar period a chronic renal disease was observed
in a group of otherwise healthy Belgian women who had
ingested a slimming regimen that included a wrong species of
CMM, Guang Fangji (Aristolochia Fangchi Radix) containing
aristolochic acid instead of Han Fangzi (Stephania Tetrandra
Radix). Over time, approximately 100 of these women
developed chronic renal insufficiency due to the toxic effects
of aristolochic acid[12]. Furthermore available in the market,
often found are CMM products adulterated with pharmaceu-
tical drugs and wrongly supplied crude CMM causing liver
and kidney toxicity[13]. These unprofessional practices from
commercial organizations do not give TCM the right reputa-
tion and recognition[14]. It is emphasized that legal regulatory
agencies should set up harmonized monographic standards for
CMM and regulatory control over the import and export of
natural or herbal products to ensure safety of the public who
consume these products[15]. Further information will be
considered in subsequent texts on this issue.
3. The requirement of expertise and leadership to
implement improvement
The advancement of internet access message on CAM is
freely available to the public. As such there is the growing
demand for and promotion of traditional and herbal
medicines including TCM products in countries within
Europe and in North America. Adverse effects and health
risks exist with the use of TCM in a western environment by
persons often unfamiliar with the underlying medical tradi-
tions. A recent review[13] indicates several key points
concerning usage status of TCM in a survey conducted by
experts in the European Union (See Box 1). Therefore, such
requirements and resources on professional experts and
leadership which determine the quality of practice and
standardised TCM medications and non-pharmacological
interventions are the pre-requisites before one can assess
the safety and efficacy of TCM treatment and prevention of
diseases in regions outside China. Global collaboration[16] is
one of the ways to look at evidence-based practice of TCM
and for integration into healthcare systems worldwide.
Box 1. A summary of key points of the EU survey on TCM status in
EU community
. Unlicensed medicines manufactured outside Europe often
do not comply with international or European quality
standards;
. herbal products used in TCM ranging from medicines,
foodstuffs, food supplements, cosmetics to borderline
products;
. major differences on legal status of Traditional Chinese
Medicine exists in Australia, China, Europe, North America
and regions with different regulatory approaches;
. a lack of harmonised requirements for the qualification,






1990s to 21st Century
and beyond
Modernisation of Chinese Medicine was initiated by the State Administration of
Traditional Chinese Medicine and various other key government organisations.
Vigorous development of all aspects of traditional Chinese medicine (TCM) led by various
government bodies.
• International Modernisation of Chinese medicine in all aspects: education and training;
basic medical scientific investigation on the biochemical and physiological aspects of
acupuncture, herbal treatment and physical therapy (Medical massage, Qigong
meditation, Taichi exercise);
• Quality control and assurance of Chinese materia medica (CMM) and proprietary
Chinese medicines (PCM) from composite formulae (FuFang) via key good practices
(GACP, GLP, GMP, GCTP); Development of experimental models to relate TCM
principles and MSM pharmacological actions of PCM products; development of
modern dosage forms; efficacy and safety of CMM and PCM products;
• Improve and promote integration approach for OM and TCM in particular on
prevention of diseases.
• Systems biology was introduced as a bridge for TCM and molecular pharmacology to
elucidate mechanisms of acupuncture and composite formulae.
• Application of functional genomics, proteomics, network-pharmacology towards
investigations of mechanisms of action for CMM and PCM.
• Integration of TCM’s diagnostic and treatment procedures from syndrome
differentiation of diseases to clinical efficacy investigations.
• Incorporate TCM Quality of Life instruments as measures of patients’ reported
outcomes linked with biomedical parameters as additional measurement of efficacy of
TCM treatments and prevention of diseases.
• Other key specific projects such as informatics for CMM and TCM practices; proper
promotion of functional food in TCM practice, life style for preventative medicine, etc.
• Integration of TCM into mainstream of healthcare and medical treatment;
establishment of integrative clinics and hospitals.
• Improvement of international networking (globalization), collaboration and
information sharing in the training, R&D and modernization of TCM.
© World Journal of Traditional Chinese Medicine Development of TCM outside the Chinese mainland
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(Box 1. Continued)
. a lack of or insufficient knowledge about the impact of TCM
in medical and pharmaceutical practices and public health;
. a need for harmonised policies on the products and practices
for consumers and patients and from surveillance of the safety
on practices and products;
. a need for specific training for TCM-prescribers, dispensers,
practitioners and therapists.
Medical Training & Research of TCM
Outside China in the 2000s
1. The inclusion of complementary & alternative
medicine in MSM
The reductionist and specialisation approach in diagnosis
and treatment of diseases in conventional MSM has been
questioned as inappropriate for holistic care for patients by
experts who are involved in medical curriculum. Since the
early 2000s the medical schools in the USA reviewed that
although evidence-based medicine remains an important part
of medical education, 123 of the 125 Association of American
Medical Colleges required students to take at least one
complementary/alternative medicine (CAM) course in the
academic year[17]. Such changes have been brought about by
the patients’ desire for alternative therapies, as nearly 40% of
American adults had used some forms of CAM, from
nutrition and mental relaxation to acupuncture, magnet
therapy, and foreign healing systems like traditional Chinese
medicine and Indian ayurveda. Medical schools in other
regions have also encouraged similar approaches, indicating
there is an increasing interest of CAM. Future practice of
MSM may embrace and encourage a holistic approach to
practice that incorporates patient involvement in self health-
care, prevention and lifestyle interventions. In most interna-
tional CAM conferences we have observed that TCM
participation in key themes mainly focuses on acupuncture,
qigong/taichi for the benefit of well-being and pain relief with
few clinical studies of TCM formulae while research out-
comes in assessing quality, safety and clinical efficacy of
TCM herbal products in CAM conferences are not plentiful.
In general, TCM as a CAM discipline is considered the most
widely used CAM worldwide[18,19]. On the other hand, most
international conferences of TCM have included a good mix
of all 5 disciplines mentioned earlier.
2. The reason for inclusion of biomedical science
in TCM curricula
Patients may be at risk from a delay in seeking medical
advice for a serious medical condition that is not appropri-
ately treated by complementary therapies. Therefore the
practitioner should be competent to recognise the need of
knowledge in both TCM and MSM practice. Professionalism
and regulations are needed to protect the public.
A consultant paediatrician, who led the clinical trial of a 10
CMM-decoction mixture in treatment of atopical eczema in
children[11] and published positive outcomes in 1992,
commented:
“Those unfamiliar with Chinese medicine should be aware
that, in present-day China, it is regarded as perfectly
normal for TCM practitioners to prescribe Western-type
licensed pharmaceutical products alongside acupuncture
and herbal therapies. There is no rigid separation of
Western-type medicine and TCM as outsiders might
imagine, and the training of TCM practitioners has for
several decades included substantial amounts of basic
Western medical science including anatomy, physiology
and pathology. Likewise, those training in China in
Western-type medicine are taught the theories of TCM.
The result is considerable cross-fertilisation between these 2
disciplines, despite their superficially exclusive natures. This
has been very much to the benefit of patients, who are not
infrequently treated simultaneously by both types of
practitioner. During my own visits to China I saw this
collaboration occurring in many areas of medicine, but
perhaps most effectively in the treatment of auto-immune
diseases such as systemic lupus erythematosus and derma-
tomyositis, which are common in China, and in the
symptomatic care of patients dying of liver failure, also
common in China, and of terminal malignant disease.”[20].
During the 1990s, such medical experts and professionals
equipped with both medical disciplines were not plentiful in
the west including UK and other regions. If there is the desire
of using TCM in the healthcare system in any developed
countries there should be training courses that produce
practitioners of TCM with good quality and professionalism
to safeguard the public interests and their health. This is to
check on those who are not qualified and to eliminate
unprofessional practice. In most European countries the
interest groups of acupuncture and TCM herbalism started
more formal training of CM on the initial running of and
updating seminars. The earliest group seminars were run
during the late 1950s and early 1960s. In recent years, many
of the established acupuncture colleges in the UK (also in
Australia and the USA) have introduced courses in TCM
herbalism. Most of these institutes run part-time courses,
mainly in the evenings and weekends, of varying years of
duration with certificates and diplomas on graduation. An
independent survey on overall situation of TCM practice in
UK indicated that available training courses, offered by
private schools/institutes, were mainly on part-time basis.
Table 3 provides a summary indicating most of the private
schools/institutes offered part-time programmes for TCM or
acupuncture training, as surveyed by Jin and co-workers[21].
3. Training of professionals in TCM outside
the Chinese mainland
3.1 The United Kingdom (UK) experience:
In 1995 the author was conferred Churchill Fellow, which
provided funding for him to take on the project “Critical
Assessment of Traditional Chinese Medicine in the East”. This
project enabled him to visits key TCM universities/institutes in
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Beijing, Shanghai, Nanjing, Chengdu and Guangzhou in
China, Tokyo and Toyama in Japan, Hong Kong, and
Taichung and Taipei in Taiwan to investigate the then
development of TCM academic programmes and research
and build up networking with key institutes[22].
The reported outcomes of the Churchill Fellowship were
announced national-wide and had indirectly initiated the
establishment of the very first university degree course in
Europe: The author, while working at the Ministry of Health
in Abu Dhabi as Director of the Zayed Complex for Herbal
Research & Traditional Medicine, was appointed Visiting
Professorship at Middlesex University (MU) in London and
was involved in engineering partnership between MU with
Beijing University of TCM to launch the full-time degree
course. Box 2 summarises key ethos of the programme.
Box 2. A summary of ethos provided by the London-Beijing degree
course
. Provide education and training to produce graduates who
will be competent, safe and caring practitioners in all
disciplines in TCM: Chinese materia medica and herbal
formulary, acupuncture and related medical manipulation
(Tuina and related physical therapies), together with life
styles (consuming CMM functional foods, practising Taichi,
or Qigong meditation);
. Provide students with a thorough preparation in the
principles and applications of TCM underpinned by suffi-
cient knowledge and understanding of current orthodox
medical anatomy, physiology, pharmacology and pathology,
(To be continued)
(Box 2. Continued)
with diagnostic processes and procedures to become a safe and
competent practitioner.
. Develop students as autonomous lifelong learners with the
professional curiosity to want to develop knowledge, under-
standing and skills and to conduct research that will underpin
evidence-based practice.
. Provide practice-experience training in Beijing TCM hospital/
clinic setting in final years of the course.
The London-Beijing course was eventually started in
1997[23], and since then several other institutes and universi-
ties in the UK have also offered accredited degree courses in
TCM linked with TCM universities in China. It has survived
the test of time and now developed post graduate training for
OM qualified professionals. Table 4 summarises the currently
available foundation and post-graduate courses of TCM
available in the UK. There is improvement in providing
academically sound human resources of TCM in UK.
However, at present the UK government via the Depart-
ment of Health published the Report on the Regulation of
Herbal Medicines and Practitioners, which has not agreed to
grant Statutory Regulation (SR) for herbal medicines and
practitioners as registered health professional alliance to
medicine.[24] It recommends continuing the voluntary Pro-
fessional Statutory Authority (PSA) to accredit herbal practi-
tioners since 2000 recommended for the House of Lords’
Science and Technology Select Committee, some 15 years
ago. Such decision indicates the herbal profession is not
recognised as part of the health profession and has created a
Table 3. TCM full time (FT) and part-time (PT) courses run by institutes in UK during the 1990s (Updated from Jin et al., 1995)[21].
No. Institution Courses Duration Contact Address
1. British College of Acupuncture Undergraduate courses in
Acupuncture & TCM
3 & 4 Year (PT) The Registrar, 8 Hunter Street
London WC1N 1BN
2. Chung San Acupuncture School Undergraduate course in
Acupuncture & TCM
3 & 4 Year (PT) 15 Porchester Gardens London
W2 4EY




FT/PT 101, Camden High Street London
NW1 7JN
4. College of Integrated Chinese
Medicine
Training in Acupuncture 6 Months (PT) The Registrar, 19 Castle Street
Reading, London RG1 7SB
5. Institute for Traditional Medicine Research & Education on Herbs PT Veronica Howard, 5 Waverley Place
Adolphus Rd, Finsbnury Park,
London N4
6. Japanese Herbal Medicine, Kohoha
School
Japanese Herbal Medicine 45 Week – 1 day
per week (360hrs.)
Ms. G D Soriano, C/o 36 Bankhurst
Road, London SE6 4XN
7. London Academy of Oriental
Medicine
Acupuncture & Chinese Herbal
Medicine
4 Year PT The Registrar, Newcourt, Street,
London NW8 7NA
8. London School of Acupuncture &
Traditional Chinese Medicine
B.Sc. (Hon.) TCM: Acupuncture 3 Year – Full time
course
The Registrar, 4th Floor, 60 Bunhill
Row, London, EC1Y 8QD
9. London School of Acupuncture &
Traditional Chinese Medicine
Post Graduate Diploma in Chinese
Herbal Medicine
2 Year – Part time The Registrar, 4th Floor, 60 Bunhill
Row, London, EC1Y 8QD
10. Northern College of Acupuncture Diploma in Acupuncture 3 Year The Registrar, 124 Acomb Road,
York YO2 4EY
11. Northern College of Herbs Part time Training course in
Chinese Herbs
2 Year The Registrar, 124 Acomb Road,
York YO2 4EY
12. Middlesex University* (Degree
courses since 1997)
Undergraduate course of TCM,
jointly run with Beijing University
of TCM
FT – 4 Years The Burroughs, London, NW4 4BT
http://www.mdx.ac.uk/courses/postgraduate/chinese-medicine.
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collective rebuttal action from the education, practitioners
and industry sectors[25]. Currently some of the full-time
courses for TCM degree courses are not on offer, most
probably due to the lack of demand from the public. This
may reflect the unfavourable decision of the UK government
on not granting Statutory Registration Authority to Herbal
Medicine. (See details depicted in Box 3 below):
Box 3. A summary of the collective points made against UK
government’s decision for not granting Professional Statutory
Authority to herbal medicines and practitioners[25].
. The most important issue facing the UK TCM practitioners
and their patients is access to good quality and safe
manufactured herbal medicines including those used in
TCM practice.
. Practitioners on a statutory register would be required to
purchase their herbs from suppliers demonstrating quality
assurance of their herbal medicines. Under statutory
regulation potent herbal medicines could be restricted to
use by those on the statutory register. This option is not
available under PSA voluntary accreditation.
. In the last two decades, practically every herbal misadven-
ture has occurred at the hands of those practising outside
the main UK voluntary registers without adequate training
or unethically. With the growing interest in and use of
herbal medicine, only statutory regulation can ensure that
the sector as a whole works to the highest standards and can
integrate herbal medicine into the healthcare systems of the
21st century.
. Herbal medicine, when used as internal medicine, like other
types of internal medicine practised in the UK, requires
statutory regulation for those who practise it. Professional
herbalists provide an important public service and the
profession should be integrated into the UK healthcare
scheme via statutory regulation at the earliest opportunity.
3.2 The Australia experience:
TCM has an established history in Australia and has
expanded rapidly in recent years. The practice was intro-
duced into Australia at the time of gold rush period as early
as 1850’s. At the Ballarat town of Victoria, a tourist spot
where the history of gold mining is maintained, the old clinic
of TCM called Bao Kan Tang is one of the major attractions.
This reflects the significance of TCM in health care in the
early history of Australia[26].
However, the practice of TCM struggles to find its place as
a complementary medicine in Australia, despite the fact that
around 30% of all complementary medicine consumers use
TCM. Over the last decade: Two in three people use
complementary medicine each year, with the complementary
medicine industry being worth $1.5–2.5 billion per
annum[27]. Of those who took complementary medicine,
around 27% used TCM[28]. Although there has been many
research groups formed across the nation and umbrella
institutions such as the National Institute for Complementary
Medicine, there has not been any major changes to encour-
age an ‘integrative’ approach to healthcare for the benefit of
the Australian public. In 2012, Australia is the first country
outside China who initiated registration of all qualified TCM
practitioners, supported by standards, codes and guidelines.
With this recognition of the profession, it would be an
enormous advantage to provide an R&D direction for
integrating the available well-tried experience-based TCM
paradigm with the increasingly advanced MSM paradigm.
Yet, only anecdotal records of success using TCM treatment
for diseases that have not been cured successfully by MSM
have been reported. In the public there had been sceptics
advocating against the use of complementary medicine due
to limited scientific evidence.
1) The first country outside China formalised the registration
of TCM. From 1 July 2012 onwards, TCM practitioners
must be registered under the Australia national registration
and accreditation scheme with the Chinese Medicine Board
of Australia, which is one of the 14 Boards answerable to the
Australia Health Practitioner Regulatory Agency (AHPRA;
http://www.ahpra.gov.au/National-Boards.aspx), and meet
the Board’s Registration Standards, in order to practise in
Australia. The AHPRA has the legal power to approve or
disapprove these courses in TCM including acupuncture,
Table 4. Current Full-time (FT) and (part-time) accredited TCM courses offered in UK under the UK Association of TCM.
1 Glyndwr University BSc Acupuncture & BSc Compl.
Therapies
FT Plas Coch Campus Mold Road
Wrexham LL11 2AW
2 Irish Institute of Chinese Medicine BSc Chinese Medicine FT/PT 105 Richmond Road Dublin 3 Ireland
3 Middlesex University BSc Acupuncture, BSc and MSc
Chinese Medicine
FT The Burroughs London NW4 4BT
4 University of Lincoln Diploma in TCM FT/PT Monks Road Lincoln LN2 5HQ
5 College of Integrated Chinese
Medicine
Graduate Diploma in Chinese Herbal
Medicine
PT 19 Castle Street Reading RG1 7SB
6 College of Naturopathy Medicine Diploma Acupuncture PT 39-41 Riding House Street London
W1W 7BE
7 Shulan College of Chinese Medicine Diploma of Chinese Herbal Medicine PT Parrs Wood Road, Didsbury
Manchester M20 5QA
8 The Chinese Medical Institute &
Register
Foundation and postgraduate courses FT/PT 101, Camden High Street London
NW1 7JN
9 University of Westminster Chinese Medicine Acupuncture BSc
Honours
FT 309 Regent Street London W1B 2HW
http://www.atcm.co.uk/education/accreditation.
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Chinese herbal medicine, and a combination of both
disciplines. (http://www.ahpra.gov.au/Education/Approved-
Programs-of-Study/Inactive-Programs-of-Study.aspx). At
present there are nine different institutes (universities as well
as colleges) throughout the country provide accredited/
approved basic bachelor degree courses. Some of these
institutes also provide opportunities for graduates and
qualified TCM practitioners to study higher/post-graduate
level degrees. Most of these degree courses also provide
placement training with TCM universities in China.
2) The Joint Chair in TCM Program in New South Wales
State (NSW): (http://sydney.edu.au/china_studies_centre/
china_express/issue_4/features/The-JCTCM-Programme-in-
NSW.shtml; accessed on 15th June 2016). To address some
of the above issues, an agreement between The University of
Sydney (USyd), Western Sydney University (WSU) and the
NSW former Department of State and Regional Development
(DSRD), now the Office of Science Research (OSR), was
initiated in 2008. The Chair had been a strategic appointment
whereby the holder of the Chair should provide national
leadership in TCM research and develop synergistic TCM
research programs at USyd and WSU. The program is jointly
funded, for a period of five years, by DSRD, USyd and the
WSU, and the projects are supported through the Faculty of
Pharmacy at USyd and the National Institute of complemen-
tary Medicine at WSU. A high level Project Plan was
developed by the Joint Chair in early 2010 and identified
strategic research priorities in TCM development under the
Joint Chair programme (See Box 4):
Box 4. Key strategic research priorities under the JCTCM
programme
. Assisting with Chinese herb cultivation to address quality
supply issues and increase the agricultural potential of
Chinese medicinal materials in Australia;
. Initiating, developing and continuing national and interna-
tional collaborations with other institutes and industry
partners;
. Investigating the background of manufacturing and analysis
methods to provide herbal product consistency and predict-
able bioactivity;
. Contributing to R&D product development (pharmacologi-
cal and clinical investigations, linking biomarkers and
patient reported outcomes);
. Contributing to the development of TCM bioinformatics
and data management to capture traditional knowledge;
. Developing the national and international profile of NSW
and Australia in TCM
. Training future human resources with TCM expertise in
research and practice
The JCTCM programme, though challenging, complex and
diverse in collaboration, has successfully achieved to provide
research and training direction for future human resources,
particularly with partners in China. The programme has
hosted a variety of TCM related public lectures, seminars,
workshops and delegations during the course of the program,
and participated in national TCM forums, all contributing to
the development of the science and evidence-based aspects of
TCM education, future and practice as well as establishing
potential collaborations between national and international
partners. During the period of the JCTCM programme,
notably the following key projects had been carried out
(See Box 5).
Box 5. Some key outcomes of the JCTCM Programme 2009–2014
. PhD students (two at USyd and one at WSU), Masters
students (one at each university) and several Final Year &
Summer project students in the two universities were
trained in R&D of TCM: including mechanistic and
pharmacological methodology, method development in
quality control of Chinese materia medica; bioinformatics
related to TCM formulary; development of Quality of life
instrument based on TCM principles for patients’ reported
outcomes research. Over 50 SCI publications were conse-
quential to these training projects.
. The JCTCM received funding support from the Australia-
China Science and Research Fund under Group Missions
category to work on “The sustainable cultivation in
Australia of high quality medicinal plants for use in
traditional Chinese medicine” with The Institute of medici-
nal Plant Development (IMPLAD) as the China partner.
. The JCTCM was appointed by the TGA to be Australia
Observer to serve as expert at the TCM Working Group at
the European Directorate for Quality Medicines and
Healthcare in drafting CMM monographs for the European
Pharmacopoeia.
3.3 The Hong Kong experience:
This has been an example of gradual development TCM
practitioners into an accredited and registrable profession
over the years. The Hong Kong Special Administrative
Region (HKSARg) in China was a British colony from 1842
to July 1997 under the Treaty of Nanjing signed by the then
Qing Dynasty. Most of Hong Kong residents (Over 90%)
are of Chinese origin and have close economic and cultural
relations with the the Chinese mainland throughout the
period. TCM as an integral part of the Chinese culture has
been widely used within the Hong Kong Chinese commu-
nity for a long time despite western MSM being the main
stream in medical care. HKSARg is also an important trade
centre port/centre of TCM related products including CMM
due to her close economic relationship with the Chinese
mainland and Chinese communities overseas. The open
policy of the Chinese mainland since the 1980s has created
many key trading channels. While China is the main
producer and exporter of CMM, Hong Kong is the most
important first destination of this import and re-export
trade. Over the past decade, after returning to the mother-
land, HKSARg has been one of the most influential regional
communities in terms of economic and technological
development and growth and has been ranked as the
world’s freest economy many years running, and it remains
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presently the first of the world’s top 5 leading financial
centres[29]. This does help to promote global appreciation of
the culture, practice and service of TCM outside China.
1) CM in Hong Kong during colonial period. During this
period, TCM was not recognised as part of the healthcare
system in Hong Kong though R&D towards quality control,
toxicology and pharmacology had been set up by the
Chinese Materia Medica Research Centre (CMMRC) at
the Chinese University of Hong Kong since the early 1980s,
which has now been re-developed to the highly recognised
Institute of Chinese Medicine. The then HK Government
appointed a Working Party on Chinese Medicine (August
1989 to October 1994) to review the practice and use of
Chinese medicine in Hong Kong and advised measures that
should be taken to promote the proper use and good
practice of Chinese medicine. Consequently, a Preparatory
Committee on Chinese Medicine (April 1995-March 1999)
was established to make recommendations to the govern-
ment on the promotion, development and regulation of
Chinese medicine in Hong Kong. The Committee recom-
mended a statutory body be set up to regulate the practice,
use and trading of Chinese medicine; a system of accredita-
tion and regulation which includes registration, examina-
tion and discipline of Chinese medicine practitioners be
established with transitional arrangements for existing
practitioners; and a control mechanism, through systems
of registration, licensing and labelling be set up to regulate
the manufacture, distribution, retail and import and export
of Chinese medicines. Regarding the future development of
Chinese medicine, the Preparatory Committee recom-
mended full-time undergraduate courses in Chinese medi-
cine be developed and made available in Hong Kong;
scientific researches and developments in Chinese medicine
be encouraged and supported; and Chinese medicine be
included into Hong Kong’s medical and healthcare system
on a gradual basis.
2) TCM in Hong Kong after return to China. After 1st July
1997, the policy for the future development of Chinese
medicine was enshrined in the Basic Law of the Hong Kong
Special Administrative Region. Article 138 of the Basic Law
provides that “… the Government of the HKSARg shall, on
its own, formulate policies to develop western and traditional
Chinese medicine and to improve medical and health
services”. The then Secretary for Health, Welfare and Food
(Now reorganised as Food and Health Bureau) conducted a
public consultation on the development of Chinese medicine
in the HKSARg in November 1997 to solicit public opinions.
Based on the Preparatory Committee’s recommendations
and public views collected in the consultation, the Chinese
Medicine Bill was introduced into the Legislative Council in
February 1999 and was passed in July the same year (http://
www.cmchk.org.hk/eng/main_deve.htm; accessed on 30th
June, 2016).
From 1998 onwards full-time degree courses in Chinese
Medicine were set up in three different local public
universities recognised by the Government University Grant
Council (HKUGC), though there were private colleges of
TCM providing part-time courses in the past. There are
presently three Schools of Chinese medicine offering
fulltime (5-years foundation plus clinical internship)
undergraduate degrees courses and par-time masters/post-
graduate course at the Chinese University of Hong Kong
(http://www.scm.cuhk.edu.hk/), Hong Kong Baptist Univer-
sity (http://scm.hkbu.edu.hk/en/home/index.php) and the
University of Hong Kong (http://www.scm.hku.hk/). All
undergraduate courses follow similar academic structure to
those specified by the State Administration of Traditional
Chinese Medicine in Beijing and placement/internship
training in their respective teaching out-patient clinics and
key TCM university hospitals in Beijing, Chengdu, Guangz-
hou, Nanjing, Shanghai, and Shenzhen. All courses are
taught in three spoken languages when necessary (Canton-
ese, English and Putonghua) with biomedical curricula
taught in English. The graduates have now fully integrated
in services either in private practice or at the outpatient-
clinics of public hospitals in the 18 districts and hospitals
run by non-government organisations. The Hong Kong
government University Grant Council has also provided
research funding to help research and development of TCM
since the mid-1990s.
In the early 2000s Hong Kong Department of Health
launched the quality assurance programme on the Hong
Kong Chinese Materia Medica Standards “HKCMMS” to
develop standards for commonly used CMM in phases to
ensure the safe use and the quality of CMM. The then Chief
Executive highlighted in his 2009 Policy Address the
importance of expediting the setting of standards for
CMM commonly used in Hong Kong. It is in this context
that the Department of Health embarked on the extension
of CMM coverage to about 200 by 2012. The 2011/12
Policy Address of the Chief Executive had reaffirmed the
government’s commitment to the establishment of stan-
dards for CMM. Recently the “Hong Kong Chinese Materia
Medica Standards (HKCMMS) Volume 7” was launched in
June 2015; seven editions of the HKCMMS covering
standards for a total of 236 CMM have been published.
The research and development works of HKCMMS are
done by institutes from local and overseas universities and
the Chinese mainland regulatory/testing institutes, and
research outcomes are deliberated and overseen by the
International Advisory Board (IAB) consisting of 23 local
and international renowned experts. The IAB gives advice
on the principles, methodologies, parameters and analytical
methods for the development of HKCMM standards. It also
decides the contents of the HKCMMS, selects the research
institutions to take up the research and laboratory work,
and determines the target medicinal plants. The IAB
usually meets once per 12 to 18 months to evaluate and
endorse the research results. The overall guided principles
are summarized in Box 6. (http://cmd.gov.hk/html/eng/
index.html, accessed 30th June, 2016)
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Box 6. Principles observed when drafting the HKCMMS
. to provide applicable and adoptable reference for the CMM
trade;
. to ensure the safety and quality of CMM in protection of
public health;
. to harmonize with the international standards; and
. to facilitate the trade in Chinese medicines.
3) The future development of TCM in Hong Kong. In the
2016 HKSARg government policy address, in response to the
requests from the academia, industry sector, and TCM
community together with the encouragement of the Nobel
Prize in Medicine received by Tu You-You’s research
outcome on QingHaoSu[30], the HKSAR Government has
been implementing the recommendations from Chinese
Medicine Development Committee in phases: a) the launch
of the Integrated Chinese-Western Medicine Pilot Project as
new initiative Chinese medicine services by the Hospital
Authority; b) the planning and establishment of a testing
centre for Chinese medicines to be administered by the
Department of Health on top of the completing the
compilation of Hong Kong Chinese Materia Medica Stan-
dards for CMM commonly used in Hong Kong, and will
launch a pilot study on the standard setting for Chinese
medicines decoction pieces; c) personnel training and
professional development, research and development for the
Chinese medicines industry; and d) reserving a site to
develop a Chinese medicine hospital. This has been a change
for the good of TCM in Hong Kong after the 1997 return
to motherland. (http://www.policyaddress.gov.hk/2016/eng/
p232.html; access 30th June 2016)
Advance of Analytical, Biomedical and
Computational Technology
The holistic integrity of CMM combination contained in
the proprietary Chinese herbal medicines (PCM), which
creates a challenge in establishing quality assessment and
control of standards of the starting materials (crude
materials and decoction pieces) and the standardization of
finished herbal drugs because no single chemical marker
component is contributing to the total efficacy of the herbal
prescription[31,32].
Analysis of complex mixtures of TCM products depends
heavily on instrumental and chemical analysis technology,
which has been the key driving force for nearly all practical
measurements in modern physical and medical sciences.
Separation technology is an essential component in phyto-
chemical analysis of ingredients in medicinal plants The
introduction of unique hyphenated-chromatographic instru-
ments coupled with sophisticated computer technology has
allowed analysts to measure the chemical contents of extracts
from herbal mixtures[33,34]. These analytical armaments have
indeed provided analytical scientists to investigate complex
mixtures in the phytochemical elucidation of ingredients in
CMM as characteristics in a single CMM or mixtures in the
finished products.
1. Application of chemometric analysis on
chromatographic finger printing
This analytical approach has enabled the generation of
chromatographic fingerprints, which represent a rational
approach for the quality assessment of TCM products.
Thus, chromatographic fingerprinting analysis of herbal
medicines has contributed a comprehensive qualitative
approach for the purpose of species authentication, evalua-
tion of quality, and ensuring the consistency and stability of
herbal drugs and their related products. The pragmatic
comprehensive chromatographic fingerprinting analysis can
disclose the detectable ingredients composition and concen-
tration distribution under quantifiable operational conditions
and therefore provide real-time quality information. How‐
ever, this cannot entirely solve the holistic actions of the
composite formulae or decoction pieces prescribed for
treatment. It may leave a “grey” entity at the primary
stage[31] Nevertheless, consecutive studies will be required
to develop feasible technology to measure activity and
improve the reliability of quality assessment and transparen-
cy of TCM products. Chemical fingerprinting pattern alone
cannot reflect entirely the quality assurance of the composite/
complex mixture products, bioactivity index to confirm the
safety and mechanisms of action is needed before large scale
of clinical studies for efficacy[35], is conducted as shown by
the following example of Phytomic QC.
2. Linking chemical and biological fingerprints
of CMM as quality assurance
Recently, Tilton and co-workers using finger-printing tech-
nology and gene-expression monitory, worked on the quality
assessment of a TCM composite formula (Huang Qin Tang)
which was developed as an product with intellectual property
protection known as PHY906[36], consisting of four distinct
CMMs: the roots of Scutellaria baicalensis Georgi. (Huang-
qin), Glycyrrhiza uralensis Fisch. (Gancao) and Paeonia
lactiflora Pall. (Baishao), and the fruit of Ziziphus jujuba
Mill (Dajao), which has been documented for nearly 1800
years for treating common gastrointestinal distress, including
diarrhoea, abdominal spasms, fever, headache, vomiting,
nausea, extreme thirst, and subcardiac distention. In addition
to traditional pharmacopoeia analyses, such as heavy metal
tests, microbial tests, pesticide residues, a multi-faceted
approach, Phytomics QC, integrates (1) high resolution
chemical fingerprint focusing on liquid chromatography/
mass spectrometry (LC/MS); (2) bioresponse fingerprint
with genomics technology on differential cellular gene
expression; (3) animal pharmacology for in vivo validation
and (4) a sensitive, quantitatively comparison method.
Phytomics Similarity Index (PSI) has been developed by
the joint efforts of Yale University and PhytoCeutica, Inc.
team to assure the quality consistency of different manufac-
tured batches of PHY906. This kind of multi-faceted
technology, trade-marked as “PhytomicsQC” is not only
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good for the quality control of such medicines, but also useful
for the discovery of new indications or the development of
new formulations. In addition to GMP conditions applied
during production, good quality control analyses should
include both chemical fingerprints and biological fingerprints
of botanicals.
Over a ten-year period of development, the multiplex
technology “Phytomics QC” has been used to show batch-to-
batch consistency of PHY906 production. Advanced clinical
trials are ongoing to demonstrate the effectiveness of
PHY906 as an adjuvant therapy for cancer patients undergo-
ing chemotherapy. PHY906 has eventually been approved by
the Food and Drug Administration (FDA) to carry out Stage
II-clinical trials[37].
The Challenge on Future Development
of TCM Outside the Chinese mainland
1. Good Practices of TCM Research in the
Post-genomic Era (GP-TCM)
The European Commission under its 7th Framework Pro-
gramme (FP7) funded the project coined as ‘Good Practice’
in TCM Research in the Post-genomic Era (GP-TCM)[38],
which assembled over 200 scientists and clinicians from 112
institutes in 24 countries (including nine non-European
countries, see Figure 1) in collaboration and discussion, who
had been actively involved in various disciplines in TCM
research and TCM practice and active in clinical research,
who took part during the period from May 2009 to October
2012. This consortium coordinated, met and deliberated how
best to collect and review the published research data available
from reliable journals, texts and reports over the good practice
of TCM researches in 10 Work-packages covering quality,
safety & toxicology, in vitro, in vivo laboratory methods,
clinical research in TCM including acupuncture, and regula-
tory aspects of TCM and herbal products.
1.1 The formation of the FP-GP-TCM and GP-TCM
Research Association
The consortium of GPTCM had provided a comprehensive
review report submitted to the European Commission and
published 20 peered review papers in the 2012 issue of Journal
of Ethnopharmacology, volume 140, which are fully accessible
to the public as an information dissimilation process[39-57].
Readers will find these 20 papers useful as they summarise
reliable aspects of TCM research and practice since the post-
genomic era and offer advice for future research and practice
directions. Subsequently this consortium has been evolved in
April 2012 to become the Good Practice in TCM Research
Association (GP-TCMRA), which has continued the coordi-
nating function of networking and collaboration with the aim
of meeting annually, alternating in Europe and Asia, to
exchange progress of TCM research work with global
scientists and practitioners. (http://www.gp-tcm.org/). The
comprehensive reports of the FP7-funded project can be
accessed using the following website below: http://cordis.
europa.eu/result/rcn/57511_en.html, accessed 30th June, 2016)
1.2 The outcomes of the GP-TCM project
The outcomes of this European funded project have been to
achieve the objectives stated in the 10 work-packages
described above, to approach and connect the multiplicity
of expertise in working on TCM research and practice. It
reflects the crucial continuing action is needed to expand
networking, cross-cultural research collaboration and open-
mindedness for scientific innovation and investigations that
link the practice of TCM to the maintenance of good health
and treatment of diseases. The key outcome of the EU
Figure 1. Distribution of GP-TCM members within and beyond the EU. (A) Fifteen EU member states were involved in GP-TCM. They were Austria,
Belgium, Denmark, Estonia, Finland, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Romania, Spain, Sweden and the UK, as highlighted
by red dots. (B) Nine non-EU countries were involved in GP-TCM, including Australia, Burkina Faso, Canada, China, D.R. Congo, Norway, Russia, Thailand
and the USA, also highlighted by red dots. [Ref: 38].
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coordination project has been the formation of the Good
Practice in TCM Research Association (GP-TCMRA), which
was established on 16th April, 2012 in Leiden, the Nether-
lands. Box 7 summarises other key future actions for
TCM development. (http://www.gp-tcm.org/2012/04/about-
association/, accessed on 30th June 2016).
Box 7. Other key issues for future TCM development
. Disease-oriented studies using the approach of multi-
indexed high-throughput technologies and systems biology
analyses will be a preferred strategy for future R&D of TCM.
. International collaboration and harmonization is essential
for regulation of good quality TCM products.
. Development, dissemination, implementation and refining
of good practice guidelines in reviewing and publishing
research findings on traditional medicine are matters of vital
importance.
. Combining the systems biological investigations of mechan-
isms of actions of Chinese medicines, ensuing identification
of potential biomarkers to be associated with both Western
disease concepts and TCM pattern classifications and QOL
instruments to monitor patient-reported outcomes, which
are in the heart of personalized medicine, would offer
common ground for integration.
. Effective pharmacovigilance is essential for the development
of appropriate guidelines for safe, effective use of herbal
medicines including those derived from Chinese materia
medica.
. Structural alerts and in silico, in vitro and in vivo methods
could be applied to predict the genotoxicity, teratogenicity
and nephrotoxicity of Chinese medicinal products.
. Research in TCM syndrome differentiation will provide the
basis of the molecular network of TCM syndrome differen-
tiation for some disease types, in defining the potential
mechanism of Chinese medicines
2. The demand of good quality herbal materials
for prescribing and manufacturing
Materia medica and herbal products, referred as botanicals in
North America, are essential phytomedicines for nearly 80% of
the world population particularly in developing countries,
where traditional medicine often depends upon[58]. Problems
and difficulties arise in the quality assurance of herbal
products due to unidentified chemical entities with unknown
bioactive components. The uncertainty of how Chinese herbal
medicine works, the safety and the incidents of adverse effects
of substituted herbs[12] have urged the authorities in some
countries to ban use of certain Chinese herbal medicinal
(CHM) products containing potent CMM. For examples the
use of Ephedra Herba and Aconitii radix and related species
are banned from even very experienced TCM practitioners to
prescribe in Australia, Northern America, UK and other
countries in Europe[59]. Ephedra herba is a commonly
prescribed CMM often in combination with other CMM in
composite formulae (Fufang) while Aconitii radix, a very
potent but useful CMM (when properly used) can only be
prescribed by very experience TCM practitioners. In the 2000s,
the Food and Drug Administration (FDA) in the USA, after
reports of several deaths of misuse as weight-reduction or
unsupervised use of over the counter supplements containing
Ephedra herba, implemented a complete ban on the CMM
(http://umm.edu/health/medical/altmed/herb/ephedra). Such
an action does affect the practice of TCM as practitioners do
not have access of this CMM for prescribing purposes.
3. Regulatory monographic standards of CMM
in various pharmacopoeias
3.1 The Chinese Pharmacopoeia (CP, The
Pharmacopoeia of the PRC)
The CMM monographs play a key role in the quality
assurance of CMM for TCM practitioners prescribing herbal
formulae (Fufang) to patients and TCM manufacturing
industry as raw materials for their production of TCM
products. One way of giving guidelines to ensure the supply
of quality-ensured CMMs is to spell out monographic
requirement assurance of herbs and herbal products. The
monographic standard of a CMM as laid down in the
Pharmacopoeia People’s Republic of China (Chinese Phar-
macopoeia, CP) is the minimum requirements for all assays
and analytical limit tests for each of the CMM included in the
CP. These include the characteristics as described in Box 8.
Box 8. Key characteristics described in a monograph of the Chinese
Pharmacopoeia[60].
For crude CMM
Name: Official name of the CMM, Pinyin name, Chinese characters
of the CMM.
Sources: Origin of medicinal plants with Latin name, collection
conditions of dried plant part.
Description: Morphological appearance mentioning shape, size,
texture, odour and taste.
Identification: Microscopic appearance of powdered CMM with
range of size/shape measurements of distinguishable character-
istics of the powdered CMM.
Analytical characteristics: HPTLC pattern; HPLC fingerprint;
Total ash value: Not more than an assigned limits determined from
ethanol extraction guided by standard procedure.
Water content: Not more than an assigned limits, determined
from ethanol extraction guided by standard procedure.
Extractives: Not less than an assigned limits determined from
ethanol extraction guided by standard procedure.
Assay limits: Not less than an assigned limits, determined by an
instrumental method (Measurable usually using HPLC, or GLC).
For processed CMM decoction pieces under the same monograph of
the crude CMM
(Limit tests are similar to those the crude CMM but including the
following descriptions)
Processing method: Assigned method or preparing the decoction
pieces.
Property and Flavour: According to TCM characteristics, e.g.
Warm; pungent etc.
Meridian tropism: e.g. acting on heart and stomach meridian.
Actions: e.g. to open the orifices and eliminate phlegm.
Indications: tinnitus and deafness, epigastric stuffiness and torpid
intake etc.
Administration and dose: ranging from 3–10 grammes.
Storage: Preserve in a dry pace; protect from mould.
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3.2 The European situation for non-TCM herbal drugs
In the EU there are monographs issued for all of them in
common use. The Commission E in Germany has produced
standard monographs for controlling herbal medicines. The
European Scientific Cooperative on Phytotherapy (ESCOP)
was founded in 1989, consisting of 14 European countries, as
an umbrella organisation representing national herbal medi-
cine or phytotherapy associations across Europe, especially in
their discussions with European medicines regulators.
ESCOP has commissioned the writing of standards provides
state-of-the-art reviews (monographs) of the therapeutic use
of leading herbal medicinal products, based on the latest
evidence and on leading expertise across Europe. Recently an
App for Apple and Android devices summarising over 100
ESCOP monograph is available to provide the uses, safety
and quality standards of many European phytomedicines.
With quality of herbal medicinal products assured the
efficacy of them can be assessed by RCT before licenses can
be issued. (http://escop.com/, accessed 30th June, 2016).
ESCOP has the advisory role but the monographs are not
legally binding with regulatory agency in Europe; they serve
as reference purposes in that if the herbal products manu-
factured according to the quality standards laid down in the
ESCOP the agency can grant clinical trial certificates for
clinical studies before registration for as legal herbal medi-
cines in the country concerned.
3.3 The European consideration on TCM drugs for
inclusion in the EP
The increasing availability of imported CMM and related
products from China in European countries recorded
approximately US$ 12 million over the last few years. They
do not fall in the same category of European herbal
medicines. As such quality control is considered an impor-
tant aspects to guarantee the safety use of TCM products by
the European Directorate for Quality Medicines & Health-
care (EDQM). The EDQM is an organisation that protects
public health by enabling the development, supporting the
implementation and monitoring the application of quality
standards for medicines and their safe use. These standards
are recognised as a scientific benchmark world-wide. The
European Pharmacopoeia provides a legal and scientific
reference for the quality control of medicines. It is legally
binding in 37 member states that have signed the Convention
on the elaboration of a European Pharmacopoeia. In addi-
tion, the observers of the European Pharmacopeia Commis-
sion (including 7 European and 17 non-European countries)
benefit from the European experience in work-sharing and
harmonisation and have access to the scientific work in the
quality control of medicines. For such guarantee on quality of
medicines dedicated to human use the European Medicines
Agency (EMA) collaborates closely with EDQM. (http://
www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_
networks/general/general_content_000574.jsp&mid=WC0b01
ac0580789733; accessed on 30th June, 2016).
The Working Party of TCM (WPTCM)[61] was created in
2008 by the Pharmacopeia Europa (Ph Eur) Commission at
the EDQM to oversee the elaboration of new Ph Eur TCM
herbal drug monographs based on pre-existing monographs
published in the Pharmacopoeia of the People’s Republic of
China (Also so known as Chinese Pharmacopoeia, CP).
Recently, it was announced by the Chairman of the WPTCM
at the International Summit of Future TCM held in Zhijiang
on 29th May 2016 that 66 monographs of CMM, out of a
total of 186 herbal drugs, have been included in the European
Pharmacopoeia; targeting up to 300 monographs in the
future. (http://www.chinanews.com/jk/2016/05-29/7887169.
shtml; accessed on 30th June, 2016).
Evidently, there exist different aspects of the details in the
deliberation of monographs between the EP and CP as
indicated by the authors[61]. This is a good indication of the
progressive cooperation in drafting pharmacopoeia mono-
graphs for Chinese materia medica between China and EU to
focus on good quality of starting materials for TCM products
in the future market of the European sector. There remains
further harmonization can be achieved on the standardisa-
tion of CMM, the starting herbal materials for TCM
prescription use and possibly for future manufacturing of
TCM products.
3.4 The North America sector and other regional
progress in drafting herbal monographs
Quite separately other institutes in the North America sector
such as the American Herbal Council, which provides critical
information for the American Herbal Pharmacopoeia, have
also included herbal monographs on TCM materials with the
help of colleagues in China and other countries focusing on
TCM and other traditional medicines giving critical reviews
on TCM herbal materials as quality assured monographs.
These monographs represent the most comprehensive and
critically reviewed body of information on herbal medicines
in the English language, and serve as a primary reference for
academicians, health care providers, manufacturers, and
regulators. It is a non-government run organisation, hence
the PDF of the monographs can be purchased online. (http://
www.herbal-ahp.org/, accessed on 30th June, 2016). On the
other hand the Herbal Medicines Compendium (HMC),
published by the U.S. Pharmacopeial Convention (USP), is a
freely available, online resource that provides standards for
herbal ingredients used in herbal medicines. Standards are
expressed primarily in monographs, containing general
information; these include: the definition of the herbal
ingredient relative to the monograph title and then follows
with a specification. The specification contains tests for
critical quality attributes of the herbal ingredient and
includes analytical test procedures and acceptance criteria
for specified tests. USP’s HMC employs validated analytical
procedures for the tests specified in its monographs, using
state-of-the-art analytical techniques and allied reference
materials. Additional analytical methods and approaches
may be referenced in general chapters, which also are
available online. Some of the key experts on TCM mono-
graphs from the CP in China also serve as USP Council
Experts, which is the body that makes the organization’s
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scientific and standards-setting decisions. When coupled
with sound registration processes and manufactured accord-
ing to suitable Good Manufacturing Practices, standards in
HMC can become an important part of the safety net that
helps ensure access to good quality herbal medicines. http://
hmc.usp.org/about/about-the-herbal-medicines-compendium,
accessed 30th June, 2016
3.5. Herbal monographs related to TCM from
other countries and regions
Countries and other regions have their own pharmacopoeia
focusing on required standards for herbal medicines and
products available in their communities. Some of these
regulations also cover TCM products. An overview the
regulations of Chinese materia medica in various countries
and regions indicated there are wide variation of require-
ments for the quality control on herbal products[15,51]. Box 9
summarises some of the key agencies, which provide
standards in their national pharmacopoeia on herbal materi-
als. The overview also suggests that the fast growing demand
worldwide for traditional medicines calls for harmonised
monographic standards to safeguard quality and safety of
herbal products to the public.
Box 9. Agencies provide on standards for herbal medicines
(Modified and updated from Reference 15)
(WHO: World Health Organisation; CFDA: State Food and Drugs
Administration, China; EDQM: European Directorate for Quality
Medicines and Healthcare, European Union; DH: Department of
Health, Hong Kong Special Administrative Region, China; MHLW:
The Ministry of Health, Labour and Welfare, Japan; TFDA: Thai
Food and Drug Administration, Thailand; BPC: British
Pharmacopoeia Commission, Medicines and Healthcare products
Regulatory Agency, UK; TGA: Therapeutic Goods Administration,
Australia; ABC: American Botanical Council, USA; NNHPD:
Natural and Non-prescription Health Products Directorate, Canada)
• WHO Monographs on
Selected Medicinal Plants
WHO Unofficial
• Chinese Pharmacopoeia, CFDA, China (CN) Official
• European Pharmacopoeia EDQM, EU Official
• Hong Kong Chinese Materia
Medica Standards
DH, HKSARG, CN Official
• Japanese Pharmacopoeia MHLW, Japan Official
• Thai Herbal Pharmacopoeia TFDA, Thailand, Official












4. Global view on adverse reactions and interactions
of TCM with pharmaceutical drugs
Traditional medical systems such as TCM have been used
with accumulated experience, and refined over a long period
of recorded clinical use, and include well-defined formulary
of processing and combination of CMM according to the
individual patients’ constitutions to maximise efficacy and
minimise toxicity. In general, such selection of CMM
perceived as harmless, some do exhibit low level or non-
symptomatic toxicity and indeed many toxic herbs showing
adverse drug reactions (ADRs) have been identified only via
painful experience or serendipity; some incidents of wrong
supply of intended material exist as in the case of aristolochia
species[12]. Because of the vast amount of herbal medicines
and related products on the worldwide market and the
variability of regulatory control of herbal products in
different regions together with poor budgets or support
available for herbal research; relatively few reports on the
basic scientific assessment of herbal products appear in the
literature or official reports from regulatory agencies. Serious
ADR events regarding TCM mainly concern those CMM
such as Aconitum species, which are used very rarely in
countries outside China because they are banned from the
market and for prescribing[59]. But these potent CMMs are
restricted to experienced-based prescribing by registered
TCM practitioners.
4.1 An overview on adverse drug reactions to TCM
In a recent overview on adverse drug reactions (ADRs) to
traditional Chinese medicines[13], it was pointed out that the
safe use of CMM and products in traditional Chinese
medicine (TCM) practice conventionally relies on correct
pharmacognostic identification, good agricultural and
manufacturing practices based on pharmacopoeia standards
and rational/correct CMM combinations with TCM-guided
clinical prescribing. The experience-based principles on using
prescribed formulae of several CMM may not absolutely
ensure safety without assurance of proper supply of the
herbal materials for detailed toxicological investigations when
compared with development of new pharmaceutical drugs.
Clinically observed toxicity reports remain as guidance for
gathering toxicological evidence, though essential as pharma-
covigilance, but are recognised as late events for ensuring
safety and can be considered for future awareness and
prevention. (See Box 10).
Box 10. High-lighted key points on ADRs in the overview
. Global development of TCM that has affected conventional
healthcare as the lay public can easily access unsupervised
treatment or health/medicinal products
. Examples of key toxic substances in some CMMs, which are
not for general availability but only for restricted TCM-
experience-based prescribing;
. Presence of wrong CMM species or contaminants such as
pesticides residues, heavy metals and other toxins in CMMs,
which fail monographic standardised limit tests, should be
rejected, are sources of ADRs in herbal medicines
. Lack of pre-clinical tests before TCM products are used vs
well-tried and experience-based TCM prescribed use.
. Regulations of ADR reporting and monitoring was formally
set up in 2004 overseen by the China National Centre for
(To be continued)
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(Box 10. Continued)
Adverse Drug Reaction Monitoring under the guidance of
CFDA, on pharmacovigilance of ADRs related to pharmaceu-
ticals and TCM products[62].
. Reported adverse drug reactions (ADRs) consequential to
taking CMM and TCM products by academic circles as
literature report/overviews may provide useful pharmacovigi-
lance reference to the occurrence of ADRs[63].
. Proposals on rational approaches to integrate biomedical
science and the principles of TCM practice for detecting early
ADRs if TCM products and orthodox drugs are involved.
. Emphasis on good control of the quality and standards of
CMM and proprietary Chinese medicines can certainly reduce
the incidence of ADRs in TCM practice when these medica-
tions are under prescribed or guided usage.
A separate expert opinion paper on issues of ADRs
methodology focused on the toxicity of herbal medicines
appears in the Science magazine, which provides guidance on
researching ADRs: “Recent advances in functional-omics and
bioinformatics now allow the investigation of efficacy and
toxicity at systems levels. The modulation of multiple path-
ways and end-points induced by numerous components can
be determined, to enable the elucidation of mechanisms of
action and potential threshold behavior for the mixtures.
When developed and validated for use on herbals, these
methods will enhance the detection of insidious toxicities,
providing the necessary background information for effective
extended pharmacovigilance of specific herbal medicines.
In vivo classical tools are still a cornerstone for toxicological
evaluation, but appear ill-suited to study multi-component
and variable herbal mixtures”[64].
4.2 Dealing with combined use of TCM and
pharmaceutical drugs in healthcare
Due to the advances of multimedia to provide information
on health and disease matters, the public are more aware or
informed, mainly via the Internet, about health and medical
products. People become more knowledgeable about matters
relating to their health conditions and well-being in curing
and preventing illnesses. The author has taken on the task of
publishing a comprehensive review, based on previously
published text book[65] and current literature, on the topic
of interactions between conventional pharmaceutical drugs
(PD) and TCM products while focusing on the harmful or
beneficial effects of such combined intake with examples
from reported clinical studies and interpretation of possible
mechanisms of actions[66]. It is feasible to set up laboratory
protocol to screen commonly prescribed CMM products
against those groups of PD with potential adverse effects
when combined with other substances. Many in vivo animal
models can be used to screen drug interactions between herbs
and drugs. Pharmacokinetic and pharmacodynamic correla-
tion may be achieved using these in vivo models. Pharmaco-
kinetic clearance of PD in presence of CMM products can be
studied using in vivo models. The data obtained are useful
qualitative guidelines and reference alerts for clinical practice
in integrative medicine involved TCM and MSM, but they
are not considered as clinically relevant in actual patient care
unless the patient’s response involved life-threatening danger
or irreversible damage. In most literature reports, when
ADRs arisen due to TCM-PD interactions or other comple-
mentary medicines alone, supportive measures are carried
out while the suspected interacting TCM or PD are
withdrawn and close observations on patient’s clinical
conditions are monitored[63]. Accumulation of individual
cases of TCM-PD interactions from clinical observations will
provide information for further laboratory confirmation. In
general PD-PD or TCM-PD interactions may produce
enhanced drug effect that is synergistic; the outcomes of
interactions may be beneficial or harmful can be classified as:
1) Major: if life-threatening or permanent damage occurs;
2) Moderate: if additional treatment is required; or
3) Minor: if the therapeutic outcome is unnoticeable or not
affecting desired therapy goals.
4.3 Harmful effects of TCM-PD interactions
Patients often self-medicate themselves with various health
products and over-the-counter medicines apart from prescribed
pharmaceutical drugs (PD). Some of those non-prescribed
products may have doubtful quality control and contain
harmful additives or unchecked ingredients such as pharma-
ceutical drugs; thus their usefulness is in doubt. The increasing
popularity world-wide of using traditional Chinese medicines
(TCM) and related over-the-counter (OTC) functional pro-
ducts has raised concerns over their concomitant use with PD
and the consequential adverse effects. In most cases the alleged
causes of ADRs are linked with herbal sources, although the
authorised information on the interactions between TCM-PD is
not plentiful in the literature. Most pharmaceutical drug-drug-
interactions are related to interference of the pharmacokinetics
and pharmcodynamics of the drugs taken simultaneously; thus
prescribers should be aware of multiple drug treatment regimes
and unintentional co-administration or self-administration.
Some of the interactions can be predicted to avoid or changed
to other treatment regime, from the properties (pharmacologi-
cal and physic-chemical as well as pharmacokinetic character-
istics). Those that cannot be predicted can be considered as
the dynamic interactions at receptors or enzymes systems not
clear or idiosyncratic outcomes related to the patient’s consti-
tution or disease status (Both MSM and TCM aspects). Key
guiding principles on dealing with available information during
treatment period are listed in Box 11.
Box 11. Key alert pointers in PD-PD and PD-TCM: Criteria, drug
groups, mechanisms
. Drug properties include: Drugs used in multi-drug regimes
drugs with narrow therapeutic window during treatment;
drugs exhibit accumulation; enzyme induction and meta-
bolic polymorphism.
. Drug groups include: Antacids, Anti-arrhythmics, Anti-
asthmatics, Anti-coagulants, Anti-convulsants, Anti-diabetics,
Anti-hypertensives, Cardiac glycosides, Cytotoxics,
Psychotropics
(To be continued)
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. Suggested mechanisms: PD-TCM forms complex leading to
treatment failure; Transport impairment causing reduced
effects TCM affecting PD diuretics & body electrolyte imbal-
ance; TCM glycosides or other ingredients destroyed by acidic
PD; TCM ingredients interfere with PD liver metabolism
resulting in enzyme inhibition/induction and alteration of PD
efficacy
4.4 Beneficial effects of TCM-PD interactions
Experience of integrated MSM and TCM medical practice in
China has provided experience of, since the 1950s through
experience of practice and recorded case studies, beneficial
treatment observations and outcomes with probable explana-
tion or possible mechanisms of interactions between TCM and
PD, although more experimental research and clinical evi-
dences are needed to confirm such observations with signifi-
cant evidence accepted by the MSM circle. This is partly
because the MSM gold standard of randomised clinical
trials (RCT) is not entirely applicable in the individualised
approaches for treatment in CM practice in personal medicine.
These case studies were abstracted from medical journals
published in China and have been translated into English and
edited by the author and co-worker for presentation in the
text[65]. The tentative categories of case studies, which illustrate
synergy effects of treatment consequential to co-administra-
tion of PD and CM medications are summarised in Box 12.
Box 12. Examples of clinical studies indicate beneficial interactions
between TCM-PD
. Antibiotics with TCM products producing added beneficial
effects
. Treating infection with antibiotics and immune-strengthen-
ing TCM products
. Augmenting cardiovascular PD treatment with TCM
products
. Augmenting anti-inflammatory action of PD with TCM
Products
. Reducing adverse effects due to PD chemotherapy of
cancers by TCM products
Many other examples of clinical cases and larger clinical
trials have been published in Chinese languages and a review
published in 2005 summarises systematically in English
language the CMM’s role to function as key TCM drugs
augmenting the beneficial contribution to the mechanisms as
beneficial agents in the treatments indicated[67].
Under these circumstances, there is an urgent need to
compile such database. The future professionals in health and
medical care should be knowledgeable or aware of what their
patients have been taking or given. In actual practice the patients
may receive both treatments intentionally or unintentionally,
with or without the awareness of the practitioner. In these
situations a reliable database for interactions between TCM-
PD will be extremely useful for consultation when integrative
TCM-PD treatment problems appear or during emergency
situations. Their combining of medications may be involved
with possible outcomes of adverse reactions or beneficial effects.
Such a database will be welcomed by both practitioners of
TCM/herbal medicines and MSM practitioners in the emerging
trend of integrative medicine[66].
5. Integrative science and medicine in future global
clinical development of TCM
To promote TCM to be accepted globally into mainstream
medicine and healthcare systems, it is important that up-to-
date science and technology can be implemented to interpret
the basis of TCM diagnosis and treatment and the assurance
of the quality, safety and efficacy of TCM products and
treatment modalities. Previous sections on the advances of
analytical, biomedical and computational aspects of technol-
ogy are equipped for the purposes of modernisation in
assurance and control of the quality and safety of CMM.
Innovative development of methodology to provide evidence
of mechanisms of actions in pre-clinical studies of TCM
composite formulae (Fufang, consisting of multiple CMMs)
and their efficacy in clinical trials as well as TCM treatment
approaches require further consideration.
5.1 Linking systems approaches in MSM and
TCM principles
The systems biology approach to MSM, recently adopted into
biomedical fields, offers the potential to investigate if the
principles can be applied to integrate with TCM[68]. The
systems biology approach of patient profiling using modern
genomics, proteomics and metabolomics technologies[69-70] is
a perfect match for the systems diagnosis in TCM[71].
Integration of these approaches may reveal different group-
ings or sub-phenotypes of patients, which require individua-
lised treatments. Moreover, knowledge about the biological
mechanisms behind the personalized herbal formulas used in
TCM is expanding through modern herbal chemical and
genomic profiling techniques[72-73].
Both TCM and MSM science describe life as a complex,
dynamic, non-linear system. As OM scientists discovered the
non-linear behaviour of cytokine networks, TCM practitioners
and scientists have recognized non-linear patterns in how
symptoms change in patients[74]. The fractal properties of the
arteries, lungs and heart rate resemble the fractal thinking in
TCM[74]. In both sciences, life is considered a self-balancing
system for organisation of body functions that is far from
equilibrium. Systems thinking can build the cultural, philo-
sophical and scientific bridges that are necessary to share
understanding between the two sciences. By studying tools and
techniques developed in both the TCM and MSM medical
systems, new insights will emerge that are necessary to heal the
patient, under his environment and the world he lives in[75-76].
5.2 Progress of biomedical and clinical studies in TCM
In a 2010 review on the situation of clinical trials of TCM in
the past decade, including systematic reviews and meta-
analyses on TCM clinical trials either focusing on the
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treatment of diseases with TCM principles approaches or
focusing on one TCM herbal product, on TCM studies either
with randomization controlled trial (RCT) methodology or
general observation, the authors observed, from the first
systematic review of TCM clinical research published in
2002[76], to more clinical trials have also been published
internationally[77], and, which has consequently increased the
number of systematic reviews (SRs) and meta-analysis of TCM
clinical trials[78].
The authors of the 2010 studies summaries the following
key points of their observations[76] (Box 13):
Box 13. Observation of TCM clinical studies over a 10 years period
. Most RCT studies of TCM have more methodological
limitations than conventional medicine according to some
reports[78], although increasing attention have been paid to
quality control of the studies;
. More RCTs with higher quality in the future to meet the
needs of modern research and development, and that the
quality of RCTs will be improved with the generalized RCT
registration, standardization of clinical research, and the
promotion of evidence-based medicine;
. The innovative design of a RCT with integrating pattern
information and disease diagnosis for group classification
according to TCM syndrome differentiation will certainly
explore more valuable contribution of TCM treatment;
. Meta-analysis as a high-level evidence would increase as
there will be increasing amount of high-level, high-quality
data to support the systematic review;
. RCT panel studies of TCM formulated products demon-
strated that monitoring biomarkers and patients reported
outcomes (PROs) before and after intervention with these
products can assess efficacy of the TCM products.
5.3 The Health-Related Quality of Life (HRQOL)
Instrument for TCM research: ChQOL
It is acceptable that Quality of Life (QOL) indicators are
often used as secondary outcome indicators in many clinical
studies in conventional MSM. However, the efficacies of TCM
treatment using conventional QOL have not been particularly
evident in TCM studies. There is a general impression among
TCM practitioners that the currently available QOL instru-
ments may not be sensitive enough to detect the health
changes that are regarded as important in treatment using
TCM. For examples, in TCM diagnosis and treatment
regimens, appetite and digestion, routine of urination and
bowel, facial and lips colour, spirit in the eyes and adaptation
to climates and seasons are very important indicators of
health status under the TCM’s diagnosis. However, these
indicators are usually not included in common health related
QOL (HRQOL) measure. Through the development of
Chinese medicine based QOL (ChQOL)[79] it is feasible to
assess patient-reported outcomes (PROs), generated from
ChQOL instrument administered to patients before and after
treatment intervention, as a measure of treatment efficacy.
PROs include not only health status and quality of life but
also reports on the satisfaction with the treatment and care,
the adherence to prescribed regimens when directly related to
end-result outcomes. Further treatment-related decisions are
based on a combination of objective and PROs subjective
parameters. The PROs concept is actually similar to one of
the four diagnostic methods in TCM: “Interrogation”, which
has been used since the beginning of TCM, and is a very
effective diagnostic and evaluation method in TCM.
The development of the Chinese quality of life (ChQOL)
instrument based on the diagnosis and treatment of TCM[79],
has allowed us to investigate its application to record patients’
feedback as patients’ reported outcomes (PROs) after the
intervention of TCM treatment or receiving TCM prescrip-
tion containing mixtures of Chinese materia medica (CMM)
or proprietary Chinese medicines (PCM). The opportunity of
recording objective and subjective outcome indicators such as
biomarker, PROs & HRQOL, and TCM practitioners’ treat-
ment records, respectively can also be applied to the evidence-
base approaches for assessing TCM treatment efficacy on
individual patient cases[79]. This instrument can be a bridge
that integrates TCM with conventional MSM and healthcare
to assess the efficacy of TCM treatment. The ChQOL
instrument has been applied to study patients with congestive
heart failure[80] and RCT panel studies of PCM of products
containing multiple CMM as a health product[81], in patient
suffering from hepatitis[82], in metabolic syndrome[83] and
asthma[84]. The evidence level of case report and panel study
will be improved and ascertained by applying innovative
analysis with modern informatics processing technologies.
These new approaches will be more suitable for case reports
and panel studies and may pave the way for ascertaining TCM
principles of holistic approaches to diagnosis and treatment of
diseases and individualized treatment for patients.
Through such integrative approaches utilizing the superi-
orities of both medical disciplines the future clinical research
and practice will be able to provide evidence-based outcomes
for TCM practice and products development.
Of particular emphasis to apply such integrative approach,
it is feasible that future development of TCM products can be
applied towards high burden diseases (See Box 14), which are
under the top healthcare agenda in most developed regions
worldwide.
Box 14. Examples of key high burden diseases
(Modified and updated from reference 66)
. Cardiovascular system (CVS): hypertensive complications;
metabolic syndrome related diseases including cardiovascu-
lar complications after stroke attacks; diabetes related CVS
complications; vascular dementia
. Central nervous system (CNS): ageing related diseases such
as Alzheimer diseases nonvascular dementia; Parkinsonism
diseases or related central nervous complications induced by
inflammation
. Endocrine system: hormone related cancers (breast, cervical,
prostatic cancers)
. Immunological system: inflammatory processes induced
complications including rheumatoid arthritis areas of
(To be continued)
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immune-suppressant medications after surgery centrally
affected inflammation-induced CNS diseases
. Transmitted diseases/infections: sexually transmitted/
contacted incidents, contaminated blood containing AIDS
virus, and Hepatitis B & C; Malaria infections; MRSA; specific
viral flu.
6. The integrative approaches for R&D of TCM
products for markets outside China
Manufacturers of TCM products are now required in China
and other countries worldwide to comply with good practice in
manufacturing (GMP). They need to ensure and ascertain the
quality of the starting CMMs are in line with the regulatory
requirement of minimum pharmacopoeia standards, with
good agricultural and collection practice (GACP). Quality
assurance of the starting CMMs including decoction pieces
and aqueous granules for TCM practitioners’ prescribing
needs is now the responsibility of manufacturers. They should
be aware of and apply the advance technology indicated under
the Section for Advance of Analytical Biomedical and Compu-
tational Technology for the quality and safety assurance of
their products according to pharmacopoeia standards, which
are the basic requirements for the initial stage for the herbal
markets to satisfy the TCM practice need of prescribing.
6.1 Develop niche TCM drugs focusing on high burden
diseases as future targets
Current worldwide research in drug discovery from medici-
nal plants involves a multifaceted approach combining
botanical, phytochemical, biological, and molecular techni-
ques. Medicinal plant drug discovery continues to provide
new and important leads against various pharmacological
targets including cancer, HIV/AIDS, Alzheimer’s, malaria.
Even with all the challenges facing drug discovery from
medicinal plants, natural products isolated from medicinal
plants can be predicted to remain an essential component in
the search for new medicines[1].
However, for TCM manufacturers to compete with conven-
tional pharmaceutical drugs counter-parts they should focus
on niche and innovative products via specific R&D pro-
grammes with patterned products line based on TCM medici-
nal plants sources whether as products from single-herbal or
multiple TCM formulae. They should also be knowledgeable
about the patent policy[85] and regulatory requirements for
registration of herbal products in the countries or regions they
aim to enter[51], which should be unique for survival of a very
drug industry worldwide. In the recently published overview
on understanding interactions of TCM-PD[66], it was pointed
out that the areas of importance and interest in integrative
approaches can focus on the high burden chronic diseases
where most national health systems in developed regions
experience high and escalating cost in the high burden diseases.
It is feasible to include those sexually transmitted and acquired
diseases consequential to contacts with contaminated blood
sources or infected environments as indicated in Box 14 where
both TCM and MSM practices can contribute with great
successes if proper collaborations can be arranged.
6.2. Improved RCT design with TCM syndrome
differentiation to stratify patient group and PROs
Disease-oriented studies using the approach of multi-indexed
high-throughput technologies and systems biology analyses
will be the preferred strategy for screening bio-active ingre-
dients in the future R&D of TCM. Combining the systems
biological investigations and functional “omics” to elucidate
the pre-clinical mechanisms of actions of Chinese medicines/
acupuncture will ensure the identification of potential bio-
markers to be associated with both Western disease concepts
and TCM pattern classifications[37,47]. When these data are
available they will provide information for design of future
clinical studies where TCM pattern differentiation will facili-
tate the stratification of patient groupings before clinical trial
investigations[57]. Guidelines for RCT trials investigating
TCM products should now be available to gear integrative
approaches in applying stratified patient groups to increase
the probability of useful outcomes[49]. Over the past decades,
increasing numbers of clinical trials on TCM treatment
efficacy have emerged and we predict that there will be
more RCTs with higher quality in the future to meet the
needs of modern research and development, and that the
quality of RCTs will be improved with the generalized RCT
registration, standardization of clinical research, and the
promotion of evidence-based medicine (EBM). The world-
wide focus on clinical trials in TCM will continue to increase.
However we are in need of modified modalities that can focus
on the assessment of TCM diagnosis and treatment outcomes
of the holistic and individual approach[76]. Based on accepted
and recognised models such as Interaction Rules Mining,
informatics analysis of data from TCM diagnosis and
treatment principles can contribute to the understanding of
how the complex mixture of CMM are related to the
principles of TCM formulary in treatment of diseases[57].
More importantly, communications between the two
different medical modalities needs to be dynamic to facilitate
optimal healthcare for the individual measures of treatment
outcomes. Including quality of life instruments such as
ChQOL[57] or disease-specific instrument with TCM char-
acteristics as a tool for monitoring patient-reported outcomes
linked to biomedical markers is another evidence-based
measurement for R&D of PCM part from measuring TCM
practice treatment indicated before[57]. The use of TCM-
specific QOL instrument coincides with the fundamental
initial diagnostic measurement in TCM of ‘asking questions’
which gathers information on the overall health conditions of
the patient. This is the heart of personalized medicine and
would offer common ground for integration[79]. All these
factors can be further linked with mathematical and compu-
tational approaches (such as chemometrics) as mentioned
earlier[31,32]. The uniqueness of TCM product development at
the R&D stages where novel extraction technology and
quality assurance with unique pattern characteristics can
provide patent rights[85]. Figure 2 illustrates the whole flow
steps in development of patentable TCM products.
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CONCLUDING REMARKS
Applying bioinformatics technology in collecting and deci-
phering TCM data depends on the collective combination of
knowledge from the fields of information technology,
biomedical sciences, statistics, and TCM practice. Combining
the strengths of each is essential to improving the quantita-
tive analysis of TCM and broadening our knowledge of the
principles that underlie its effectiveness. Continuing feedback
between the scientists and practitioners in each field will help
us to refine the analytical techniques used for evaluation.
Good practice in bioinformatics focusing on TCM will
integrate the data from various disciplines of TCM practices,
R&D investigations of quality control and standardisation,
mechanistic studies, ADRs reports, and regulatory require-
ments as well as training skills for practitioners will provide
valuable information for future modernisation of TCM. The
use of good quality big data for future reference and analysis
will give bench-marks for improvement and adjustment in
order to keep up with advances in biomedical fields[86].
The way forward to identify evidence-base in TCM
practice requires multidisciplinary collaborations among
different professionals of both MSM and TCM practices
with expertise from biomedical, bioinformatics, pharmaceu-
tical and TCM disciplines. There is still a lack of human
resources to take up the integrative medical research and
practice worldwide. The new wave of general practitioners
should be trained in the practice and science of TCM with
integrative medicine knowledge. If mainstream medical
practitioners have some understanding of the principles of
TCM, which is supported by scientific methodology, there
would be less opposition and more acceptance of TCM
practice. The creation of collaborative networks is vital to
overcome these differences so that international, multi-centre
clinical trials are comprehensively planned and executed.
These opportunities will help define workable integrative
medical models for future clinical practice settings.
Due to the advances in biomedical, chemical and compu-
tational technology, multidisciplinary approaches for investi-
gating evidence-based aspects of TCM practice are
essential[87]. Research linking the quality control in the
manufacturing of TCM products[88], relatively new systems
biology and experience-based TCM principles is vital to
interpret the holistic approach of TCM towards its
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Figure 2. A scheme proposed for future development of TCM products for high burden diseases.
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integration into mainstream medicine[47,69,71]. However, to
achieve these objectives, an integrative approach is crucial to
connect the multiplicity of expertise. Networking, cross-
cultural research collaboration and open-mindedness are
needed to support the scientific innovation and investigations
that link the holistic practice of TCM to the maintenance of
good health and treatment of diseases. Continuing effort in
combined scientific methodology and TCM practice in R&D
is the key to providing new knowledge for training the newer
generation of human resources in integrative medicine that
involves TCM practice.
ACKNOWLEDGEMENT
The Author declares that the presented materials have duly
been referenced from literature and public websites and there
is no conflict of interest with any organisations. He is
currently Visiting Professor in Natural Products & TCM
Research at the School of Pharmacy & Biomolecular Sciences,
Liverpool John Moores University, L3 3 AF, UK and Adjunct
Professor in TCM Research at the National Institute of
Complementary medicine, Western Sydney University, NSW
2550 and Faculty of Sciences, University of Technology
Sydney, NSW 2007, Australia.
REFERENCES
1. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life
Sciences 2005;78:431–441.
2. Chan K, Lee H. Chapter 1: The Historical Evolution of Chinese
Medicine and Orthodox Medicine in China, In: The Way Forward for
Chinese Medicin. UK: The Taylor and Francis Group, 1st Edition,
2002:1–21.
3. Williamson EM, Chan K. (2014) Chapter 9: A brief review of the
evolution of herbal medicine in European and its relationship with
modern medicine. In: Phytotherapies: Efficacy, Safety and Regulation,
edited by Iqbal Ramzan. American: John Wiley Inc, 2014.
4. American Chemical Society International Historic Chemical Land-
marks. Discovery & Development of Penicillin. http://www.acs.org/
content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.
html (accessed 28th December, 2015)
5. WHO. WHO Traditional Medicine Strategy 2014-2023. ISBN 978 92 4
150609 0;2013.
6. Robert Thong’s SciTechStrategy Blog. Root causes of the pharmaceu-
tical R&D productivity crisis. http://scitechstrategy.com/2015/03/root-
causes-of-the-pharmaceutical-rd-productivity-crisis/ (accessed 17th
February, 2016)
7. Chan K. Chinese medicinal materials and their interface with Western
medical concepts. Journal of Ethnopharmacology 2005;96(1–2):
1–18.
8. Helmut Kaiser Consultancy. Traditional Chinese Medicine with Over-
view Worldwide: Market, Development, Products and companies.
Homepage: (www.hkc22.com); E-mail: hku-tuebingen@t-online.de.
9. Collins FS, Green ED, Guttmacher AE, Guyer MA. A vision for future
genomics research. Nature 2003;422:1–13.
10. Chan K, Robinson N. How can we optimise research integrating TCM
with conventional healthcare practice? Forschende Komplementar-
medizin 2013;20(Suppl1):59.
11. Atherton DJ, Sheehan MP, Rustin MH, Whittle B, Guy MB. Treatment
of atopic eczema with traditional Chinese medicinal plants. Pediatric
Dermatology 1992;9(4):373–375.
12. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D,
Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D,
Vanhaelen- Fastre R, Vanhaelen M. Rapidly progressive interstitial
renal fibrosis in young women: Association with slimming regimen
including Chinese herbs. Lancet 1993;341(8842):387–391.
13. Chan K, Zhang H, Lin Z-X. An overview on Adverse drug reactions
to traditional Chinese medicines. British Journal of Clinical Pharma-
cology 2015;80(4):834–843.
14. Chan K. Some aspects of toxic contaminants in herbal medicines.
Chemosphere 2003;52(9):1361–1371.
15. Chan K, Leung KSY, Zhao SS. Harmonization of monographic
standards is needed to ensure the quality of Chinese medicinal
materials. BMC-Chinese medicine 2009;4:18.
16. Chan K, Hu X, Razmovski-Naumovski V, Robinson N. Challenges and
opportunities of integrating traditional Chinese medicine into main-
stream medicine: A review of the current situation. European Journal
of integrative medicine 2015;7(1):67–75.




18. Scheid V, MacPherson H. Integrating East Asian medicine into
contemporary healthcare. United Kingdom: Churchill Livingstone,
Elsevier; 2011.
19. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ et al. Historical
perspective of traditional indigenous medical practices: the current
renaissance and conservation of herbal resources. Evidence Based
Complementary and Alternative Medicine 2014;2014(1):525340.
20. Atherton D. Chapter 19. An orthodox practitioner’s view of Chinese
medicine. In: The Way Forward for Chinese Medicine, edited by Chan
K & Lee H. Publisher: The Taylor and Francis Group, 1st Ed 2002,
ISBN: 0-415-27720-5, p397–411.
21. Jin Y, Berry M, Chan K. Chinese herbal medicine in the UK.
Pharmaceutical Journal 1995;255(Suppl.):R37.
22. Chan K. Critical assessment of traditional Chinese Medicine in the Far
East, An official report submitted as the fulfillment of Churchill Traveling
Fellowship. London: Sir Winston Church Memorial Trust 1996.
23. Lee H, Chan K. A curriculum model for teaching and training Chinese
medicine in English language. In: The Way Forward for Chinese
Medicine, edited by Chan K & Lee H, 1st Ed Chapter 18. Publisher:
The Taylor and Francis Group 2002:379–395. ISBN: 0-415-27720-5.
24. Report of the UK Herbal Medicines and Practitioners Working Group.
[https://www.gov.uk/government/publications/advice-on-regulating-
herbal-medicines-and-practitioners] (published on 26th March 2015).
25. Public Statement from dissenting members of the Herbal Practitioner
and Medicines Working Group to Department of Health (DH). https://
www.gov.uk/government/publications/advice-on-regulating-herbal-
medicines-and-practitioners.
26. Li GQ, Duke C, Roufogalis BD. The progress of Chinese medicine in
Australia. In: The Way Forward for Chinese Medicine, edited by Chan
K, Lee H; Publisher: The Taylor and Francis Group, 1st Ed Chapter 10,
2002:379–395, ISBN: 0-415-27720-5.
27. The National Institute of Complementary Medicine, Western Sydney
University, Australia:www.nicm.edu.au.
28. Zhang AL, Story DF, Lin V, Vitetta L, Xue CC. A population survey on
the use of 24 common medicinal herbs in Australia. Pharmacoepide-
miology and Drug Safety 2008;17(10):1006–1013.
29. Hong Kong SAR ranks first at the index of world economic freedom.
https://en.wikipedia.org/wiki/Index_of_Economic_Freedom (access on
11th April 2016)
30. Gallaway E, Cyranoski D. Anti-parasitic drugs sweep Nobel prize in
medicine 2015. Nature News & Comments 2015;526(7572):
174–175.
31. Liang YZ, Xie PS, Chan K. Perspective of Chemical fingerprinting of
Chinese herbs. Planta Medica 2010;76(17):1997–2003.
32. Liang YZ, Xie PS, Chan K. Chromatographic fingerprinting and
metabolomics for quality control of TCM. Combinatorial Chemistry
& HTS 2010;13(10):943–953.
33. Wilson ID, Brinkman UA. Hyphenation and hypernation: the practice
and prospects of multiple hyphenation. J Chromatography A 2003;
1000(1–2):325–356.
© World Journal of Traditional Chinese Medicine Development of TCM outside the Chinese mainland
2016 |Vol. 2 | Issue 4 26 www.wjtcm.org
34. Phalke P, Kavade S. Review of hyphenated techniques. International
Journal of Chemical Studies 2013;1:157–161.
35. Chan K. Generating fingerprinting from analytical techniques alone is
not enough in the assurance for quality, efficacy and safety of
Chinese medicinal herbs and herbal products. Analytical Sciences
2001;17(Suppl.):a409–a412.
36. Tilton R, Paiva AA, Guan JQ et al. A comprehensive platform for
quality control of botanical drugs (PhytomicsQC): a case study of
Huangqin Tang (HQT) and PHY906. BMC-Chinese Medicine 2010;
5(1):1–15.
37. Lam W, Busson S, Guan F, Kiang Z, Zhang W, Gullen EA, Liu S,
Cheng Y-C. The four-herb Chinese Medicine PHY906 reduces
chemotherapy-induced gastrointestinal toxicity. Science Translational
Medicine 2010;2(45):2841–2857.
38. Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T,
Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM,
Cheng YC, Xu Q. Traditional Chinese medicine research in the post-
genomic era: Good practice, priorities, challenges and opportunities.
Journal of Ethnopharmacology 2012;140(3):458–468.
39. Verpoorte R. Good Practices: The basis for evidence-based medicines.
Journal of Ethnopharmacology 2012;140(3):455–457.
40. Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I,
Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P. Good
practice in reviewing and publishing studies on herbal medicine, with
special emphasis on traditional Chinese medicine and Chinese
materia medica. Journal of Ethnopharmacology 2012;140(3):
469–475.
41. Zhao Z, Guo P, Brand E. The formation of daodi medicinal materials.
Journal of Ethnopharmacology 2012;140(3):476–481.
42. Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A,
Liang X, Sendker J. The potential of metabolic fingerprinting as a tool
for the modernisation of TCM preparations. Journal of Ethnophar-
macology 2012;140(3):482–491.
43. Ouedraogo M, Baudoux T, Stévigny C, Nortier J, Colet JM, Efferth T,
Qu F, Zhou J, Chan K, Shaw D, Pelkonen O, Duez P. Review of
current and “omics” methods for assessing the toxicity (genotoxicity,
teratogenicity and nephrotoxicity) of herbal medicines and mush-
rooms. Journal of Ethnopharmacology 2012;140:492–512.
44. Shaw D, Graeme L, Pierre D, Elizabeth W, Chan K. Pharmacovigilance
of herbal medicine. Journal of Ethnopharmacology 2012;140(3):
513–518.
45. Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D,
Duez P. Pharmacovigilance practice and risk control of Traditional
Chinese Medicine drugs in China: Current status and future
perspective. Journal of Ethnopharmacology 2015;83(4):262–266.
46. Barlow DJ, Buriani A, Ehrman T, Bosisio E, Eberini I, Hylands PJ. In-
silico studies in Chinese herbal medicines’ research: Evaluation of in-
silico methodologies and phytochemical data sources, and a review
of research to date. Journal of Ethnopharmacology 2012;140(3):
526–534.
47. Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X,
Simmonds MS, Carrara M, Tejedor N, Lucio-Cazaña J, Hylands PJ.
Omic techniques in systems biology approaches to traditional
Chinese medicine research: Present and future. Journal of Ethno-
pharmacology 2012;140(3):535–544.
48. Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos
Centenera G, Kumari R, Xu Q, Cheng X, Watson S, Lucio Cazaña FJ.
MEDLINE-based assessment of animal studies on Chinese herbal
medicine. Journal of Ethnopharmacology 2012;140(3):545–549.
49. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G.
Guidelines for randomised controlled trials investigating Chinese
herbal medicine. Journal of Ethnopharmacology 2012;140(3):
550–554.
50. Luo H, Li Q, Flower A, Lewith G, Liu J. Comparison of effectiveness
and safety between granules and decoction of Chinese herbal
medicine: A systematic review of randomized clinical trials. Journal
of Ethnopharmacology 2012;140(3):555–567.
51. Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov
VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia
W, Dias A, Wong VC, Chan K. Future development of global
regulations of Chinese herbal products. Journal of Ethnopharmacol-
ogy 2012;140(3):568–586.
52. Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q,
Fan TP. Omics and its potential impact on R&D and regulation of
complex herbal products. Journal of Ethnopharmacology 2012;
140(3):587–593.
53. Jia J, Yu Y, Deng JH, Robinson N, Bovey M, Cui YH, Liu HR, Ding W,
Wu HG, Wang XM. A review of Omics research in acupuncture: The
relevance and future prospects for understanding the nature of mer-
idians and acupoints. Journal of Ethnopharmacology 2012;140(3):
594–603.
54. Robinson N, Lorenc A, Ding W, Jia J, Bovey M, Wang XM. Exploring
practice characteristics and research priorities of practitioners of
traditional acupuncture in China and the EU-A survey. Journal of
Ethnopharmacology 2012;140(3):604–613.
55. Liu SH, Cheng YC. Old formula, new Rx: The journey of PHY906
as cancer adjuvant therapy. Journal of Ethnopharmacology 2012;
140(3):614–623.
56. Booker A, Johnston D, Heinrich M. Value chains of herbal medicines-
Research needs and key challenges in the context of ethnopharma-
cology. Journal of Ethnopharmacology 2012;140(3):624–633.
57. Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, Chan K. Syndrome
differentiation in modern research of traditional Chinese medicine.
Journal of Ethnopharmacology 2012;140(3):634–642.
58. Bodeker G, Ong CK, Grundy C, Burford G, Shein K. WHO Global
Atlas of Traditional, Complementary and Alternative Medicine Kobe,
WHO Publications 2005;118(11):947.
59. Kim EJ, Chen Y, Huang JQ, Li KM, Razmovski-Naumovski V, Poon J,
Chan K, Roufogalis BD, McLachlan AJ, Mo SL, Yang D, Yao M, Liu Z,
Liu J, Li GQ. Evidence-based toxicity evaluation and scheduling
of Chinese herbal medicines. Journal of Ethnopharmacology 2013;
146(1):40–61.
60. Pharmacopoeia of the People’s Republic of China 2015 (Set of 4,
Chinese edition), published by China Medical Science & Technology
Press, 6/2015, ISBN/ISSN: 9787506773379/97850677430/9787506
773362/9787506775397.
61. Wang M, Franz G. The role of the European Pharmacopoeia (Ph EU)
in quality Control of traditional Chinese herbal medicine in European
member states. World Journal of Traditional Chinese Medicine 2015;
1(1):5–15.
62. Zhang L, Wong LY, He Y, Wong IC. Pharmacovigilance in China:
current situation, successes and challenges. Drug Safety 2014;37(10):
765–770.
63. Chan K, Zhang H, Lin Z. Treatments used in complementary and
alternative medicines. Side Effects of Drugs Annuals 2014;33(1):
745–756.
64. Williamson EM, Chan K, Xu Q, Nachtergae N, Brunel V, Zhang L,
Ouedraogo M, Nortier J, Shaw D, Liu X, Stévigny C, Kahumba J,
Pelkonen O, Duez P. Integrated toxicological approaches to evaluate
the safety of herbal medicine. In: The Art & Science of Traditional
Medicine Science 2014;S21–S23.
65. Chan K, Cheung L. Interactions between Chinese Herbal Medicinal
Products and Orthodox Drugs, Taylor & Francis Group, September 11,
2000 by CRC Press, 176 pages, Authors: Kelvin Chan, Lily Cheung;
ISBN 9789057024139 Ca#TF3184.
66. Chan K. Understanding interactions between Chinese medicines and
pharmaceutical drugs in integrative healthcare. Chinese Journal of
Integrative Medicine 2015;21(2):83–89.
67. Jiang WY.Therapeutic wisdom in traditional Chinese medicine: a
perspective from modern science. Trends in Pharmacological Sciences
2005;26:558–563.
68. Clish CB, Davidov E, Oresic M, et al. Integrative biological analysis of
the APOE*3-leiden transgenic mouse. OMICS 2004;8(1):3–13
69. Wang J, van der Heijden R, Spruit. Quality and safety of Chinese
herbal medicines guided by a systems biology perspective. Journal
Ethnopharmacology 2009;126(1):31–41.
www.wjtcm.org 27 2016 |Vol. 2 | Issue 4
World J Tradit Chin Med 2016; 2(4): 6–28 K. Chan
70. Chang WT, Thissen U, Ehlert KA, et al. Effects of growth conditions
710 and processing on ehmannia glutinosa using fingerprint strategy.
Planta Medica 2006;72(5):458–467.
71. Verpoorte R, Choi YH, Kim HK. Ethnopharmacology and systems
biology: a perfect holistic match. Journal of Ethnopharmacology
2005;100(1–2):53–56.
72. Callard R, George AJ, Stark J. Cytokines, chaos, and complexity.
Immunity 1999;11(5):507–513; Higgins JP. Nonlinear systems in
medicine. Yale Journal of Biological Medicine 2002;75(5–6):
247–260.
73. Van der Greef J. Systems biology, connectivity and the future of
medicine. Systems Biology (Stevenage) 2005;152(4):174–178.
74. Van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based
systems biology and personalized medicine: moving towards n = 1
clinical trials? Pharmacogenomics 2015;7(7):1087–1094.
75. Nestler G. Traditional Chinese medicine. Med Clin North Am
2002;86:63–73.
76. Jiang M, Yang J, Zhang C, Liu BY, Chan K, Cao HX, Lu AP. Clinical
studies with traditional Chinese medicine in the past decade and
future research & development. Planta Medica 2010;76:2048–2064.
77. Shen YH, Nahas R. Complementary and alternative medicine for
treatment of irritable bowel syndrome. Canadian family physician
Medecin de famille canadien 2009;55:143–148.
78. Leung KF, Liu FB, Zhao L, Fang JQ, Chan K, Lin LZ. Development and
validation of the Chinese Quality of Life Instrument. BMC-Health &
Quality of Life Outcomes 2005;3(26):1–19.
79. Zhao L, Chan K. Building a bridge for integrating Chinese medicine
into conventional healthcare: Observations drawn from the develop-
ment of the Chinese quality of life instrument. American Journal of
Chinese Medicine 2005;33(6):897–902.
80. Zhao L, Leung KF, Liu FB, Chen J, Chan K. Responsiveness of the
Chinese quality of life instrument in patients with congestive heart
failure. Chinese Journal of Integrative Medicine 2008;14(3):173–179.
81. Chui SH, Chan K, Wong RS. A panel study on the effects of a
Chinese medicinal suppository, Vigconic VI-28, on insulin-like growth
factor-1 and homocysteine in healthy men. Methods and Findings in
Experimental and Clinical Pharmacology 2004;26(5):349–355.
82. Chui SH, Chan K, Chui AKK, Shek SL, Wong RNS. The effects of a
Chinese medicinal suppository (Vitalliver) on insulin-like growth
factor-1 and homocysteine in patients with hepatitis B infection.
Phytotherapy Research 2006;19(8):674–678.
83. Chui SH, Chow FS, Chan K, Fu S, Seto YS. Slimpid may boost plasma
IGF-1 level and improve the quality of life in patients with risk of
developing metabolic syndrome. Journal of Complementary &
Integrative Medicine 2008;5(1):1987–2002.
84. Chui SH, Chan K, Shek SL, Zhao L, Fong MY, Hui I, Shum S. A panel
study to assess the quality of life assessments in patients suffering
from allergic rhinitis after treatment with a Chinese herbal nasal drop.
Phytother Res 2010;24(4):609–613.
85. Silins G, Tan J, Chan K. Intellectual property and patent issues with
phytotherapy products. In: Phytotherapies: Efficacy, Safety and
Regulation, edited by Iqbal Ramzan. Chapter 23: Publisher: John
Wiley Inc,2014. ISBN: 978-1-118-26806-3.
86. Chan K, Poon J, Poon S, Jiang M, Lu A. An Overview on Evidence-
Based Medicine and Medical Informatics in Traditional Chinese
Medicine practice. In: Data Analysis for Traditional Chinese Medicine
Research (ed. Poon J, Poon S) 2013: 227–248. (http://www.springer.
com/978-3-319-03800-1).
87. Guo DA, Han JY (2015). Integration of Traditional Chinese medicine
and modern science is the way forward. World Journal of traditional
Chinese medicine 2015;1(2):1.
88. Zhang Z, Liang Y, Xie P, Chau F, Chan K. Chromatographic
fingerprinting and chemometric techniques for quality control of
herbal medicines. In: Data Analysis for Traditional Chinese Medicine
Research (ed. Poon J, Poon S) 2014:133–154. (http://www.springer.
com/978-3-319-03800-1).
© World Journal of Traditional Chinese Medicine Development of TCM outside the Chinese mainland
2016 |Vol. 2 | Issue 4 28 www.wjtcm.org
